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IN VIVO KINOME SCREEN REVEALS NON-CANONICAL CDK-DRIVEN METABOLIC 
ADAPTATION IN BRAIN METASTASIS 
 
  
Frank Joseph Lowery III, BS 
Advisory Professor: Dihua Yu, MD, PhD 
 
Brain metastasis, which frequently arises from breast cancer, lung cancer, melanoma, and 
colorectal cancer, remains a severely unmet medical need and its incidence continues to rise 
while treatment options remain palliative. To better understand the biology underlying its 
aggressive, incurable nature, I performed an unbiased in vivo kinome screen to identify 
potential driver kinases of experimental brain metastasis in a nude xenograft model using the 
human breast cancer cell line MDA-MB-231. Several of the kinase pools led to decreased brain 
metastasis-specific survival in nude mice, shortening survival time by up to 50% relative to 
controls. Targeted next-generation sequencing (NGS) was performed to analyze pre- and post-
injection MDA-MB-231 cells, thus identifying 31 kinases that were significantly enriched in 
multiple animals. To validate the clinical relevance of these potential targets, kinase expression 
was analyzed in a collection of 32 clinical breast cancer, lung cancer, and melanoma brain 
metastases by RNA sequencing (RNA-seq); all but two of the kinases were expressed in brain 
metastases from all three types of primary tumor. Based on its enrichment in vivo and high 
expression in brain metastasis across cancer types, I chose to focus on PCTK1 as a potential 
driver. PCTK1 is expressed during spermatogenesis and neuronal differentiation but reports of 
its roles in cancer are limited. While overexpression of PCTK1 in MDA-MB-231 cells did not 
affect proliferation under routine cell culture conditions, it led to a faster rate of brain metastasis 
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growth and thereby decreased mouse survival time by 75%. The Cancer Genome Atlas (TCGA) 
data analysis revealed a potential link between PCTK1 expression and glutamine metabolism 
and I demonstrated that the growth advantage conferred by PCTK1 was due to increased 
glutamine consumption by the cancer cells. Knockdown of PCTK1 in the brain metastatic 
HCC1954Br breast cancer cell line increased mouse survival time in an experimental brain 
metastasis model, indicating that PCTK1 may indeed represent a potential therapeutic target 
for brain metastasis. In conclusion, this study identified PCTK1 as a novel driver of brain 
metastasis and exposed a means of cancer cell survival in the nutrient-restricted brain. 
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Chapter 1: Introduction 
1.1 Breast Cancer 
1.1.1 Breast cancer epidemiology 
 Breast cancer is a common and frequently deadly malignancy. In 2016, approximately 
246,660 American women will be diagnosed with invasive breast cancer (IBC) and nearly 
40,450 women will die of this disease. Breast cancer can occur in men as well, but the incidence 
and mortality rates are 100 times lower than in women (1). These statistics actually represent 
improvement over the last 30 years, as early detection and advances in treatment regimens 
have resulted in the decline of age-adjusted death rates from a peak of greater than 33 deaths 
per 100,000 women in 1989 to around 21 deaths per 100,000 today. However, it must not be 
discounted that the gains in survival rates have largely been manifested in early-stage breast 
cancer, while advanced breast cancer continues to be incurable.  
Breast cancer incidence is similar among non-Hispanic white and black women in the 
United States, although there is a large disparity in mortality rates, with white women at 21.9 
deaths per 100,000 and black women at 31 (1). While the reasons for this disparity are 
unknown, a partial explanation may come from the increased prevalence of the more lethal 
triple-negative breast cancer (TNBC) within this group (2). Strikingly, Asian-American, Hispanic-
American, and Native American women show lower incidence of and mortality due to breast 
cancer than non-Hispanic white and black women in the United States, although the effect on 
mortality is almost entirely due to the decreased incidence. These numbers are exemplary of 
the importance of both genetic and environmental factors in the risk of developing breast 
cancer. 
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Figure 1. Estimated cancer deaths in the United States in 2016. Breast cancer is the 
second-leading cause of death among in the United States, behind only lung cancer. Reprinted 
with permission from American Cancer Society, Cancer Facts & Figures 2016. 
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Figure 2. Trends in cancer death rates among females in the United States through 2012. 
Breast cancer mortality rates have declined since the early 1990s, as the advent of 
mammograms and targeted therapies led to earlier detection and more effective treatment. 
Rates are age-adjusted to the United States population in 2000. Reprinted with permission from 
American Cancer Society, Cancer Facts & Figures 2016. 
 
 Breast cancer risk rises substantially with age, as both breast cancer incidence and 
mortality increase after age 60 (3). This risk association with age is not exclusive, however. 
While younger (<40 years old) women only account for 5% of IBC diagnoses (4), breast cancer 
was the most common cause of cancer-related deaths in this population in 2011, according to 
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the latest available statistics. Additionally, breast cancer occurring before the age of 40 is more 
likely to be associated with genetic mutations in breast cancer susceptibility genes BRCA1 and 
BRCA2 and/or a family history of breast cancer. Therefore, while the majority of breast cancer 
deaths occur after the age of 50, a substantial number of life-years lost to breast cancer are 
from those diagnosed at earlier ages. 
The differences in age-adjusted breast cancer risks have recently been the focus of a 
public health controversy in the United States. Namely, while mammograms have been 
demonstrated to enable earlier detection of breast cancer ((5)) and early detection is known to 
be a key predictive factor in long-term survival, two leading organizations, the American Cancer 
Society (ACS) and the US Preventive Services Task Force (USPSTF), have recommended that 
women of average risk begin regular mammography-based screening at a later age (45 or 50, 
respectively) instead of the previous guidelines suggesting that screening start at age 40 (6, 7). 
These decisions were based upon the findings that low number of cancers detected in younger 
women does not warrant the cost of regular screening, both in terms of health care expenses 
and the emotional toll of false-positive tests. It will take some time for the results of this change 
in policy to become apparent, but one would expect that breast cancer incidence (that is, 
clinically detected breast cancer) may see a decrease in the population of women under 50 
years old with a possible concomitant rise in breast cancer mortality rates for the same group. 
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Figure 3. Screening and adjuvant therapy have both decreased the incidence of breast 
cancer over time. Comparison of models of breast cancer death rates among women age 30-
79 with or without inclusion of mammogram and/or adjuvant therapy (tamoxifen, chemotherapy, 
or both) estimated the lives saved as 25 per 100,000 per year, compared to only 12 for either 
factor alone. Note that the population considered here is women age 30-79, so the estimated 
death rate from breast cancer is higher than in previous figures which included the whole female 
population. Reprinted with permission from Berry DA, Cronin KA, Plevritis SK, Fryback DG, 
Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Intervention Cancer, 
& Collaborators Surveillance Modeling Network. “Effect of screening and adjuvant therapy on 
mortality from breast cancer.” The New England Journal of Medicine. 2005 Oct 
27;353(17):1784-92.  
 
1.1.2 Breast cancer features and clinical characteristics 
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The stages of breast cancer at diagnosis, which heavily impact treatment options and 
prognosis, range from Stage 0 to Stage IV. This staging is determined by both the size and 
spread of the primary tumor. Stage 0 represents carcinoma in situ, in which cancerous cells are 
found in either the duct or lobe of the breast, but have not invaded into the surrounding tissue. 
Stage I refers to primary tumors 2 cm or smaller, and, if any tumor cells are found in the nearby 
lymph nodes, the clusters are 2 mm or less. Stage II encompasses tumors 0-5 cm that have 
spread to 1-3 axillary lymph nodes, as well as those less than 2 cm that are not detected in the 
lymph nodes. Stage III represents tumors of any size that have spread to more than 3 axillary 
lymph nodes, as well as tumors greater than 5 cm that have spread to any lymph nodes. 
Additionally, cancer that has spread to the skin of the breast or the chest wall is classified as 
Stage III. Stage IV comprises breast cancer that has spread beyond the breast and lymph 
nodes and metastasized to bone, lungs, liver, brain, or other organs. (3) 
 
Table 1. Stage-specific breast cancer survival rates in women in the United States. 
Stage 5-year relative survival rate 
0 100% 
I 100% 
II 93% 
III 72% 
IV 22% 
 
Adapted and reprinted with permission from American Cancer Society, Cancer Facts & Figures 
2016. 
 
Breast cancer is divided into three main clinical subtypes based on histological and 
pathological criteria. These subtypes, along with disease stage, dictate the standard of care. 
The major subtypes are luminal, basal, and HER2, which are classified according to the 
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expression of 3 cell surface proteins: estrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 (HER2) (8). General characteristics are included in 
Table 2.  
 
Table 2. Clinical characteristics of breast cancer subtypes. 
Molecular Subtype 
 Luminal HER2 Basal 
Gene 
expression 
pattern 
High expression of 
hormone receptors and 
associated genes (luminal 
A>luminal B) 
High expression of 
HER2 and other 
genes in amplicon 
 
Low expression of 
ER and associated 
genes 
High expression of 
basal epithelial 
genes, basal 
cytokeratins 
 
Low expression of 
ER and associated 
genes 
 
Low expression of 
HER2 
Clinical 
features 
~70% of invasive breast 
cancers 
 
ER/PR positive 
 
Luminal B tend to be higher 
histological grade than 
luminal A 
 
Some overexpress HER2 
(luminal B) 
~15% of invasive 
breast cancers 
 
ER/PR negative 
 
More likely to be 
high grade and 
node positive 
~15% of invasive 
breast cancers 
 
Most ER/PR/HER2 
negative (‘triple 
negative,’ TNBC) 
 
BRCA1 dysfunction 
(germline, sporadic) 
 
Particularly common 
in African-American 
women 
Treatment 
response and 
outcome 
Respond to endocrine 
therapy (but response to 
tamoxifen and aromatase 
inhibitors may be different 
for luminal A and luminal 
B). 
 
Response to chemotherapy 
variable (greater in luminal 
B than in luminal A). 
 
Respond to 
trastuzumab 
(Herceptin) 
 
Respond to 
anthracycline-
based 
chemotherapy 
 
Generally poor 
prognosis 
No response to 
endocrine therapy or 
trastuzumab 
(Herceptin) 
 
Appear to be 
sensitive to platinum-
based chemotherapy 
and PARP inhibitors 
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Prognosis better for luminal 
A than luminal B. 
Generally poor 
prognosis (but not 
uniformly poor) 
Modified and reprinted with permission from Schnitt SJ. “Classification and prognosis of 
invasive breast cancer: from morphology to molecular taxonomy.” Modern Pathology. 2010 
May;23 Suppl 2:S60-4. 
 
 While these molecular subtypes of breast cancer are based on a rather simplistic 3-
gene signature, even advanced analysis of a large data set of tumors by The Cancer Genome 
Atlas (TCGA) Network, which incorporated genomic, transcriptomic, proteomic, and 
epigenomic signatures, failed to tangibly improve upon these classifications (9). Other recent 
studies in have delineated up to 10 separate subtypes (10), but this molecular gerrymandering 
has not yet elucidated any new actionable theme within breast cancers, and instead has only 
served to re-emphasize their heterogeneity. To further this point, the only genes commonly 
mutated in >10% of all breast cancer were in TP53, PIK3CA, and GATA3; the only other gene 
mutated in >10% of any subtype of breast cancer was MAP3K1 in luminal A (9).  
The lack of clarity generated by these large-scale studies is likely based on the fact that 
the broad subtypes represent breast cancers with different cells of origin, while the narrower 
grouping is further subsetting the tumors beyond their originating cells (11). These narrow 
groupings could hold promise in terms of identifying therapeutic responders and non-
responders, but it would require careful post-hoc analysis of well-designed clinical trials, and 
the fact that such subtyping is transcriptome-dependent would necessitate the messenger RNA 
(mRNA) profiling of trial subjects. However, as an example of this potential, the TCGA analysis 
did identify 2 smaller subsets of TNBC that did not cluster with basal-like breast cancer: claudin-
low and normal-like (9, 12). Claudin-low cancer is a subtype of TNBC that proliferates more 
slowly than basal-like cancer (13); normal-like TNBC molecularly resembles normal breast and 
is negative for cytokeratins 5 and 6 and the epidermal growth factor receptor (EGFR) (14). In a 
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small study, normal-like TNBC had a favorable prognosis compared to basal-like (14). If such 
differential prognoses are true in larger trials, and immunohistochemically amenable markers 
are identified beyond genetic signatures, it may allow for their regular employment in clinical 
practice (15).  
 
Figure 4. Breast cancer subtypes originate from cells of different stages of mammary 
development. (left) Subpopulations of normal breast tissue and potential cells of origin for the 
intrinsic subtypes of breast cancer; these cells may represent a stage of developmental arrest 
for a tumor with an origin earlier in the differentiation hierarchy or, alternatively, transformation 
of a cell type at one specific stage of development. (center) The various breast tumor subtypes 
molecularly compared to subpopulations from normal breast tissue. (right) The defining 
expression patterns of luminal, mesenchymal or claudin-low, and basal-like cells. Reprinted 
with permission from Prat A & Perou CM. “Mammary development meets cancer genomics.” 
Nature Medicine. 2009 Aug;15(8):842-4. 
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Choice of breast cancer therapy is dependent upon stage at diagnosis, subtype, and 
previous treatments. It can consist of surgery to excise the primary tumor and conserve the 
remainder of the breast in the case of small, localized tumors or extend to radical mastectomy 
(removal of the whole breast) with neoadjuvant or adjuvant therapy (including radiotherapy, 
chemotherapy, and/or targeted therapy). Radiotherapy is delivered locally in the case of early-
stage breast cancer in hopes of ensuring that any residual cancer cells following surgical 
resection of the tumor are killed, while chemotherapy is given in an attempt to kill unseen tumor 
cells that may have spread to the bloodstream. Both chemotherapy and radiotherapy serve as 
regular means of treatment for cancers that have invaded beyond the breast, whether to the 
lymph nodes or to secondary organs. 
In addition to these classic treatment strategies, targeted therapies may be used 
depending on the breast cancer subtype. Targeted therapies seek to disrupt the pro-growth or 
pro-survival pathways that imbue cancer cells with growth advantages, and they attempt to do 
so in a way that is less toxic to normal cells than chemotherapy does. For ER-positive breast 
cancer, endocrine therapy, either by targeting the estrogen receptor itself [as in tamoxifen, a 
selective estrogen receptor modulator (SERM)] or perturbing the availability of its ligands 
(aromatase inhibitors such as letrozole or exemestane), is frequently used in treatment at all 
stages. Because proteins called kinases, which activate other downstream target proteins by 
post-translational modification known as phosphorylation, frequently play pro-growth and pro-
survival roles in cancer cell signaling, they serve as common targets of small molecule 
inhibitors. One such inhibitor, the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib, 
has recently been approved for treating advanced hormone receptor-positive breast cancer 
(16). HER2-overexpressing breast cancers have a number of therapeutic options targeting the 
receptor, including trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), and 
lapatinib. Trastuzumab serves as the first-line therapeutic option, but the other therapies can 
serve as backup options in case of cancer progression. TNBC is unfortunately defined by its 
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lack of molecular targets for targeted therapy. However, it has exhibited higher rates of 
pathological complete response (pCR) following neoadjuvant chemotherapy regimens (17) that 
included platinum-based compounds or taxanes (18-20). Furthermore, TNBC frequently 
exhibits defects in DNA repair proteins BRCA1 and BRCA2, and clinical trials attempting to 
promote synthetic lethality by treating with inhibitors of the DNA repair protein poly-ADP ribose 
polymerase (PARP) are ongoing (21, 22). Despite the existence and continued development of 
these and other therapies, breast cancer that spreads to secondary sites remains incurable (3).  
Like other cancers, genetic instability and its resulting heterogeneity are the primary 
reasons why it tremendously difficult to treat breast cancer. In this vein, it is quite telling that the 
most common mutations in breast cancer are to TP53, which encodes the protein p53, 
nicknamed the “guardian of the genome.” Loss of function of this or other tumor suppressors, 
such as BRCA1 or BRCA2, which are frequently mutated in hereditary breast cancer, allow 
mutant cells that would otherwise either repair their DNA or die to instead continue proliferating, 
creating daughter cells that are more and more genomically unstable and phenotypically 
diverse. This genomic instability and its resulting biological heterogeneity make cancer cells 
incredibly fit when exposed to the crucibles of evolutionary selective pressure, whether they 
come in the form of differing tumor microenvironments throughout the body or therapeutic 
agents targeting distinct mechanisms of tumor growth. It is due to this fact that unless the target 
of a therapy is totally indispensable to cancer cells for survival, they will find a way survive 
without it and become resistant.  
The best example of the acquired resistance phenomenon in cancer is the use of 
imatinib in chronic myelogenous leukemia (CML). CML arises from cancer cells with a single 
translocation of chromosome 9 and 22 [t(9,22)] that causes the kinase domain of Abl to be 
constitutively activated downstream of the breakpoint cluster region on chromosome 22 (BCR-
Abl). Imatinib targets this mutation-driven cell growth and has transformed the treatment of 
CML, doubling its 5-year survival from 31% in the pre-imatinib era to 63% in 2011, and serving 
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as the best clinical example of a targeted therapy in action. However, even in this best-case 
scenario wherein a single gene translocation represents the driving agent of cancer, resistance 
still occurs through a number of mechanisms. This situation has played out similarly in breast 
cancer, where aromatase inhibitor treatment leads to mutations causing constitutive activation 
of the estrogen receptor, and where HER2 targeting in HER2+ breast cancer can lead to 
resistance to up to four available therapies. Cancer has thus far proved impossible to cure once 
it is no longer confined within the primary site, when it is no longer amenable to surgical removal. 
Even the best, most promising targeted therapies tried to date have ultimately fallen short in 
the game of molecular whack-a-mole. 
 
1.2 Metastasis 
1.2.1 Clinical background 
 While the vast majority of cancer funding and public attention are directed towards the 
treatment and prevention of primary cancer (23), the sad truth is that 90% of cancer mortality 
is due to metastasis, the spread of cancer to secondary organ sites (24). In primary cancers 
affecting organs related to reproduction (e.g., breast, ovary, or prostate), which are necessary 
for propagation of the species but non-vital at an organismal level, metastasis is the cause of 
nearly all cancer-related deaths. With few exceptions, which will be addressed later, metastatic 
cancer represents a terminal diagnosis; to emphasize this point, metastatic cancer patient 
advocates have begun referring to themselves as “lifers” (25, 26).  
Metastasis is typically considered to be late event in cancer progression, but this is 
highly dependent upon cancer type and the associated capabilities of screening and early 
detection. Imaging-based methodologies, including magnetic resonance imaging (MRI), 
computed tomography (CT), and positron-emission tomography (27), are useful in detecting 
cancer earlier than was possible in the past, but limitations of these technologies mean that 
tumors must usually reach a diameter of at least 4-7 mm for detection (28, 29). While a 5 mm 
tumor seems small, a lesion of that size is expected to contain upwards of 1.25x107 cells (30). 
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Given cancer’s enormous genomic instability and biological heterogeneity, 12 million cells are 
more than capable of proving evolutionarily fit.  
Varied methods of screening and detection as well the natural history of different types 
of cancer are manifested in the stages at diagnosis of different cancers. For example, cancers 
with either screening tests available and in regular practice (breast and prostate) or relative 
ease of observation (melanoma) are more likely to be detected and diagnosed prior to stage 
IV, with only 6% of breast cancer and 4% of prostate cancer and melanoma are diagnosed at 
the metastatic stage. Conversely, cancer types where regular screening is either not performed 
or patients are diagnosed late due to symptom confusion, e.g., cancers of the esophagus, 
stomach, or small intestine, are often diagnosed at stage IV and carry a markedly poorer 
prognosis. Indeed, this is evident in a comparison of 22 primary cancer types in the National 
Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) database, which 
shows that there is a strikingly negative correlation between the percentage of patients of a 
given cancer type diagnosed at stage IV and 5-year survival. The fact that stage IV cancer 
carries a worse prognosis is unsurprising, but that such a comparison yields an R2 value of 0.45 
is almost shocking. Independent of tumor biology or therapy available for different types of 
primary cancer, the presence of metastasis at the time of diagnosis in a subset of patients is 
highly correlated with survival outcomes in the whole cohort.   
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Figure 5. Negative correlation between percent of patients diagnosed with stage IV 
cancer and the five-year survival of all patients of that tumor type. Linear regression 
performed on data from SEER (SEER 18 2005-2011). Solid line represents the regression y = 
-0.3956x + 42.66, R2 = 0.45. Dotted lines indicate 95% confidence interval. Tumor types 
representing substantial departures from the line of best fit are indicated on the plot. 
 
 One of the most sobering implications put forth by this data is the sheer level of 
determinism that currently exists between the presence of metastasis and the likelihood of 
mortality due to said metastasis. If current therapies could significantly affect the long-term 
survival of cancer patients with metastasis, no such linear relationship would be evident. 
However, metastatic cancer is typically treatment-refractory, as it is composed of tumor cells 
that have progressed and grown under the artificial selective pressure of chemo-, radio-, or 
targeted therapy and/or the natural selective pressure the microenvironment of a secondary 
organ. Therefore, metastasis represents a substantially different population of cancer cells than 
the primary tumor from which it originated.  
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The ending that befalls metastatic cancer patients is unimaginably painful. As the tumor 
cells outcompete the resident cells comprising the body’s essential organ systems, patients 
ultimately succumb to organ failure. This failure can be brought about by metastasis to the 
bones, which first leads to risk of fracture due to structural erosion and later to suppression of 
the body’s ability to maintain its hematopoietic and immune systems as the cancer cells 
overtake the bone marrow (31, 32). The lungs are incredibly hardy and resilient, able to allow 
for survival even when tumor burden reduces their capacity by up to 75% (with continuous 
supplemental oxygen); however, when overtaken by metastasis they eventually cannot keep 
up with the body’s need for oxygen. Patients may die due to lack of oxygen, lung infection, or 
heart failure (33-35). Liver metastasis can be fatal when the liver parenchyma is replaced by 
tumor tissue, preventing essential metabolic functions and leading to multi-organ system failure, 
metabolic acidosis, renal insufficiency/renal failure, or total liver failure (36, 37). Brain 
metastasis carries the worst prognosis; its lethality is attributed to neurological losses of 
function, headache, seizure, cognitive or motor dysfunction, and coma (38, 39). In addition to 
directly causing death, metastasis across cancer types can also increase the risk of infection, 
heart failure, pain medicine overdose or other complications. Thus far, treatment is largely 
palliative; there is little chance of long-term survival for those diagnosed with metastatic 
disease. What it is it that makes this diagnosis so dramatically worse than primary cancer? 
What exactly is so unique about metastasis that has made it such an insurmountable 
challenge? 
 
1.2.2 The biology of metastasis 
 One of the key concepts of metastasis was described in the seminal work “The 
Distribution of Secondary Growths in Cancer of the Breast” by Stephen Paget, a 19th century 
English surgeon (40). Paget observed the records of 735 women who had died of breast cancer, 
and noted a strong preponderance of metastases to the liver and lungs. He looked at a further 
244 lethal cases of gynecological cancer and noted again a high proportion of liver metastases. 
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He examined the contemporary literature and found that metastasis to bone was also quite 
common, and that only specific bones were affected. He reasoned that the preferential growth 
of metastases at certain sites was due to interactions between the unique “seeds,” i.e., the 
cancer cells, and a receptive “soil,” the anatomic location of successful metastasis, not to 
random chance. This idea stood in stark contrast to the accepted wisdom of the time, which 
held that patterns of metastatic spread were due to simple patterns of vascular flow. While his 
work was at first rejected, Paget’s “seed and soil” hypothesis was rediscovered and validated 
by Dr. Isaiah Fidler in the 1970s and 80s. Fidler’s experiments demonstrated that only rare 
populations of cells within a tumor are capable of forming metastases (41), even when 
introduced directly into the circulation (42). His studies further showed that site specificity was 
not due to the circulation dynamics; even following the transplantation of different organs 
subcutaneously or intramuscularly into recipient mice prior to intravenous (i.v.) injection of 
tumor cells, thus normalizing the cancer cells’ access to the target, cancer cells maintained 
their original organ tropism (43). 
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Figure 6. The seed-and-soil nature of metastatic organotropism. Some common cancer 
types are included with their most frequent sites of metastasis. Direction of arrows indicates 
spread from primary to metastatic site. Reprinted with permission from Wikimedia Commons.  
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 As suggested previously, the process of metastasis represents an evolutionary 
challenge to potentially metastatic cancer cells. Fortunately, the degree, diversity, and number 
of these physical constraints on would-be metastatic cancer cells make the process 
tremendously inefficient. For this reason, cancer cells capable of initiating metastases have 
been likened to decathlon champions (44). A schematic of the steps required for the successful 
initiation and formation of metastases, reprinted from (44), is included as Figure 7. 
 
 
Figure 7. The metastatic cascade. Successful establishment and growth of metastasis at 
secondary organ sites requires that cancer cells fulfill 10 evolutionarily challenging steps. 
Reprinted with permission from Talmadge JE & Fidler IJ. “AACR Centennial Series: the biology 
of cancer metastasis: historical perspective.” Cancer Research. 2010 Jul 15;70(14):5649-69. 
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 The initial steps of the metastatic cascade are common to all transformed cells that grow 
beyond even a few millimeters in diameter (45). Following cell transformation, cells need to 
obtain oxygen and nutrients to survive and meet their needs for energy consumption and 
biomass generation. Due to the limits of oxygen diffusion through tissue, which can be as low 
as 100 µm (46), any cells beyond this distance from existing blood vessels would be unable to 
survive and proliferate (47, 48); for this reason tumors cannot grow larger than 2-3 mm without 
an adequate blood supply (49). Dr. Judah Folkman first connected the presence of blood 
vessels around growing tumors to tumoral release of a factor that would later be identified as 
vascular endothelial growth factor (VEGF) (50). While the means by which tumors acquire their 
blood supply has proven to be more varied than simply VEGF release (51, 52), the requirement 
of an adequate blood supply to support tumor growth is recognized as one of cancer’s hallmarks 
(45).  
 Even a well-vascularized tumor abundant in mutations does not usually pose a threat if 
it remains stationary and confined to its site of origin (53), with the exception being tumors that 
grow locally but produce deleterious effects due to their physical size interfering with normal 
physiological functions (54). In fact, it is the distinction between invasiveness and non-
invasiveness of tumors that determines a malignant or benign diagnosis. Dr. Lance Liotta 
demonstrated that only malignant cancers are able to degrade their basement membrane (BM) 
and invade into the surrounding vasculature (55). Later studies determined that the causative 
agents in BM degradation and invasion were matrix metalloproteases 2 and 9 (MMP2/9) (56). 
As an aside, in addition the tumor classifications of benign versus malignant, a classification of 
“pre-malignant” refers to transformed cells that are more likely to become invasive over time 
given the accumulation of additional genetic aberrations. Some cancers have relatively well-
characterized evolutionary courses, whereby development of additional mutations can be 
correlated with a progressive increase in malignancy; these characterizations are referred to as 
Vogelgrams, after Bert Vogelstein who first used it to describe the sequential genetic changes 
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and malignancy of colorectal cancer (CRC) in 1990 (57). The progression of increasing genomic 
mutational events corresponding with increased malignancy can be observed in CRC and 
cancers of the breast, prostate, esophagus, and cervix, among others, which are preceded by 
the premalignant lesions colorectal adenoma, carcinoma in situ [ductal carcinoma in situ (DCIS) 
or lobular carcinoma in situ], prostate intraepithelial neoplasia (PIN), Barrett’s esophagus, and 
cervical dysplasia, respectively. However, detection of a pre-cancerous lesion with mutation X 
does not guarantee the accumulation of subsequent mutations Y and Z or subsequent 
progression to later stages in these diseases. This is important clinically, as overtreatment of 
premalignancies such as DCIS and PIN and the associated loss of quality of life is one of the 
main arguments against the earlier implementation of mammography for early detection of 
breast cancer (58) and fanatical adherence to the results of prostate specific antigen (59) 
screening for prostate cancer (60); the inability to determine which pre-cancers will progress to 
invasive cancer mirrors the lack of predictability of which invasive cancers will metastasize. 
Underscoring the evolution of both invasive cancer and metastasis is the fact that cancers are 
genetically unstable and biologically heterogeneous, making it currently impossible to predict 
which mutations will arise next in any tumor; even the father of the Vogelgram has deemed the 
genetic mutations arising during cancer progression as stochastic (61). 
  
 
 
Figure 8. Vogelgram of common genetic events occurring during development of CRC. 
Ovals show oncogenic changes while rectangles show pathological state. Reprinted from 
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Wikimedia Commons with permission and based upon Fearon ER & Vogelstein B. “A genetic 
model for colorectal tumorigenesis.” Cell. 1990 Jun 1;61(5):759-67. 
 
 The study of circulating tumor cells (CTCs) is becoming increasingly popular, as meta-
analyses of large patient cohorts have demonstrated prognostic significance in the ability to 
detect CTCs in the blood, with counts of >5 CTCs in 7.5 mL of blood yielding a negative 
prognostic value in both breast and ovarian cancer (62, 63). Though the detection of high CTC 
counts leads to a statistically significant hazard ratio (HR) of  approximately 2 for overall 
survival, this still implies that 33% of patients dying from disease will actually have low CTCs, 
and that not all of those with high CTC counts are at risk. Thinking logically about the inefficiency 
of the metastatic process, it is unsurprising that quantification of CTCs, which enter the 
circulation relatively early in the metastatic cascade, would not be a perfect indication of 
mortality due to metastasis. Following invasive cancer cells’ acquisition of the ability to degrade 
the basement membrane and invade the vasculature, they are still unlikely to be able to survive 
in the circulation, much less form metastases. A previous study demonstrated that <0.1% of 
cancer cells injected directly into the bloodstream of mice remain viable 24 hours post-injection 
(42). Even granting direct vascular access to tumor cells in humans by the use of peritoneal 
shunts to alleviate the pain of malignant ascites of ovarian cancer did not result in death due to 
metastasis (64). One of the key barriers to survival in the bloodstream is the requirement for 
anoikis resistance. Anoikis is a form of programmed cell death resulting from loss of cell-to-
extracellular matrix (ECM) contact. Usually, cell-ECM contact provides cells with integrin-
mediated survival and growth signaling (65). Once this connection is lost, they will soon undergo 
apoptosis. Successful metastatic tumor cells must overcome this invasion-control mechanism 
in order to survive in the bloodstream, and one way to do so is by forming multicellular 
aggregates. The cells of these tumor emboli can provide each other with the pro-survival signals 
required to live in the absence of ECM contact (66). Additionally, cancer cell aggregation with 
either other tumor cells or hematopoietic cells can protect tumor cells from shear stress in the 
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blood (67, 68). Multiple experimental systems have shown the increased efficiency of 
multicellular aggregates at seeding metastasis compared to the same number of single cells 
(69, 70) and aggregates are detectable in patients (71-73). Recently, single-cell sequencing 
has shown that the tumor cell aggregation occurs oligoclonally, suggesting that aggregates are 
formed prior to tumor cell entry into the bloodstream (73).  
 The aggregation of tumor cells in the blood can also help the potentially metastatic tumor 
cells negotiate the next challenge in the cascade, arresting within the vasculature of secondary 
organs. The journey of tumor cells through the circulation ends one of two ways and both 
involve getting stuck. One method is vascular occlusion, which occurs when a cancer cell or 
cell cluster physically blocks the vessel in which it is traveling because its diameter exceeds 
that of the vessel (74, 75). The second means of arrest within blood vessels is the adhesion to 
vessel walls, a process similar to that employed by immune cell adhesion and displayed in 
Figure 9 (76). Briefly, according to fluid dynamics, shear stress is higher near a boundary, in 
this case the blood vessel wall. At that same point, the blood flow rate will be lower (77). So 
while blood flowing through large vessels is traveling at a seemingly impossibly fast rate for 
receptor-ligand binding to occur, cells that bounce close to the walls of the blood vessel actually 
slow and are pushed toward the wall by shear forces. If the immune or tumor cells express cell 
surface carbohydrates (frequently in the form of selectin ligands) compatible with those of the 
endothelial cells (selectins), they begin to roll more slowly along the vessel wall. When tight 
receptor-ligand binding occurs, such as that mediated by integrins, they firmly adhere to the 
vessel wall (78). Interestingly, a study of brain metastasis revealed the top gene changed 
between cancer cells metastatic to the brain versus other organ sites was ST6GALNAC5, which 
encodes a molecule that mediates adhesion specifically to the brain vasculature (79). 
Additionally, while tumor cells may adhere to the vascular walls through their own actions, this 
binding may also be mediated by platelets, which express selectins and selectin ligands (74). 
23 
 
Indeed, platelets have long been known to play pro-metastatic roles (80-82); their status as 
adhesion mediators is key to successful metastasis.     
 
Figure 9. The process employed by tumor cells in adhering to walls of the vasculature is 
similar to that used by immune cells. In this process, cells traveling through the vasculature 
at high rates of speed occasionally bump into the vessel walls. If cell surface ligands (boxed 
with dashed line) meet their counter-receptors on endothelial cells, the cells will slow and begin 
a rolling motion along the vessel wall. When the leukocyte or cancer cell binding avidity exceeds 
the shear force of the blood flow, firm adhesion is achieved and the cells may be able to 
extravasate. Reprinted with permission from Geng Y, Marshall, JR, & King MR. 
“Glycomechanics of the metastatic cascade: tumor cell-endothelial cell interactions in the 
circulation.” Annals of Biomedical Engineering. 2012 Apr;40(4):790-805. 
 
Once cancer cells have disseminated into the vasculature of secondary organs, they 
still need to be able extravasate into the organ parenchyma if they are to form true metastases. 
This act of extravasation occurs in two steps: breach of the blood vessel wall, followed by the 
physical migration out of the vessel. The migration out of the vessel is a simple matter of 
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following chemokine gradients into the tissue (83); the chemokines present are tissue-specific 
and thus demand different phenotypes from the tumor according to the organ involved, a 
situation analogous to the extravasation of immune cells into target tissues (84). Using a chick 
embryo chorioallantoic membrane model of metastasis, it was shown that human cancer cells 
send small cytoplasmic actin-containing protrusions, termed invadopodia (85), through the 
junctions of endothelial cells in order to breach the blood vessel wall enter into the surrounding 
organs (86). This vascular breach can be enhanced through cancer cell secretion of VEGF or 
tumor necrosis factor-α (TNF-α), which can weaken the endothelial cell tight junctions and/or 
increase the subsequent tumor cell motility (87, 88). 
Finally, followed extravasation, tumor cells have technically made it into the organ 
parenchyma of a secondary organ site. If they are compatible with their new environment, they 
may grow, develop their own blood supply, and even invade and spread further throughout the 
body--metastasis of metastasis. However, this step in the metastatic cascade is actually the 
most demanding of would-be secondary tumor. Upon dissemination and entry into the 
secondary site, cancer cells still have to adapt to their new environment, which is highly unlikely 
to be reminiscent of the setting of the primary tumor, and may include dramatically altered 
nutrient resources and populations of resident cells that inhibit invasive cancer cells both 
directly and indirectly. Additionally, as was true of growth at the primary site, if metastases are 
to grow greater than a few millimeters in diameter, they will require their own blood supply. 
Evidence of the exceptionally inefficient nature and the challenges posed at this step come from 
multiple clinical and experimental observations. First, in an experimental model, less than 
0.04% of cancer cells introduced into the circulation were able to form lung metastases, and it 
was estimated that only around 20% of cells that were able to survive in the secondary organ 
site went on to successfully form lung nodules (42). Xenograft studies in mice showed that 
disseminated cancer cells that survived at secondary organ sites without forming detectable 
metastases, when isolated from these non-metastatic organ sites and injected into recipient 
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animals, were able to form spontaneous overt metastases (89). This so-called ‘dormancy’ is 
one mechanism cancer cells may use to survive for long periods of time if the conditions in a 
secondary organ are not optimal for growth, either in terms of availability of oxygen, nutrients, 
or growth factors or due to active inhibition by host cells (e.g.  immunosurveillance) (90). 
Dormancy may also take two distinct forms: mass dormancy refers to those disseminated 
micrometastases that either cannot obtain the blood supply or nutrition to grow beyond a few 
millimeters, or are being held in check by immunosurveillance; cellular dormancy refers to 
quiescent cells that have exited the cell cycle but remain viable (90).The concept of dormancy, 
although difficult to model and study experimentally, also would account for clinical 
observations on the timing of metastatic recurrence (91, 92). In breast cancer, it has been 
shown in multiple large studies that there is a bimodal peak of metastatic recurrences, with 
highest incidences at 18 months and 5 years following initial therapy (93). However, there 
remains a non-zero risk of metastatic outgrowth more than 10 years following initial diagnosis, 
and multiple studies have reported the appearance of overt metastases more than 20 years 
following initial cancer diagnoses (92, 94-97). The role of immunosurveillance in suppressing 
metastasis at the secondary site has been shown in humans following organ transplantation, 
as organ recipients with no prior history of malignancy develop metastatic tumors in their grafted 
organs (98-100). In each case, it has been shown that the organ donor had a primary cancer. 
When the organ recipients were put on immunosuppressive drugs in order to prevent organ 
rejection, the immunological suppression of these dormant cancer cells was abrogated and the 
cells outgrew in the recipient, in several cases actually killing the organ recipient. In summary, 
when cancer cells at secondary sites overcome whatever barriers are preventing their 
outgrowth, through adaptation to the secondary site or changes to the site itself brought on by 
such processes as aging, inflammation, or immunosuppression, they have achieved the 
completion of the metastatic decathlon and can grow into overt metastases (101).   
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Figure 10. Timing of metastatic recurrence in breast cancer. Left panel shows the hazard 
ratio of metastatic recurrence (blue) plotted with local recurrence (red). Right panel shows that 
the timing of metastatic recurrence is similar for bone (top, solid line), visceral organs (middle, 
dotted line), and soft tissue (bottom, dashed line). X-axis shows months post-initial diagnosis, 
Y-axis is hazard ratio. Reprinted with permission from Demicheli R, Biganzoli E, Boracchi P, 
Greco M, & Retsky MW. “Recurrence dynamics does not depend on the recurrence site.” Breast 
Cancer Research: BCR. 2008;10(5):R83. 
 
 It is evident from the rigorous functional demands of the metastatic cascade that the 
evolutionary champions of such a process are unlikely to represent the same population of cells 
from which they are derived, and the data have served to support this principle. It was 
demonstrated that different clonal populations within a primary tumor have different abilities to 
form metastasis (41), and that only a single metastatic clone (102, 103) or oligoclonal cluster 
(73) is required to serve as the founder of a metastatic tumor. The disconcerting implication of 
this fact is that even the best technologies interrogating genomic, transcriptomic, and proteomic 
analyses of primary tumors are unlikely to yield predictive data on whether and where a primary 
tumor could be expected to metastasize. Profiling of metastases, however, has shown that their 
gene expression patterns differ from their associated primary tumors (104, 105) and even led 
to some elucidation of the mediators of permissive seed and soil interactions hypothesized by 
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Paget (79, 106). Coupled with the fact that metastases frequently arise as cancer recurrences, 
following the development of therapeutic resistance, the disparate gene expression by 
metastases and their associated primary tumors can also help explain the dismal prognosis of 
metastasis: metastases can possess both de novo (107) and acquired resistance (108) to 
therapies to which primary tumors and even other metastases respond (109-111). Interestingly, 
in a case of the seed and soil theory at work, cells of the metastatic microenvironment can even 
protect these secondary tumors from therapy, as is the case with astrocytes serving 
chemoprotective roles during brain metastasis (112). Indeed, one of the only examples of 
successful (albeit not curative) therapeutic targeting for metastasis involves not direct targeting 
of tumor cells, but the more stable metastatic microenvironment in bone. Bone metastatic 
cancer cells hijack the physiological bone remodeling process in order to obtain growth factors 
from the bone matrix (113); remodeling involves the degradation of bone by osteoclasts and 
the deposition of new bone by osteoblasts (114). In bone metastasis, cancer cells stimulate the 
osteoclasts into excessive activity (113); the weakening of bones and associated risk of fracture 
was noted by Paget as evidence for his seed and soil theory (40). Using therapeutic agents, 
including bisphosphonates, denosumab, and dasatinib, that target the osteoclasts themselves 
instead of the cancer cells has delayed skeletal-related events, such as fracture, associated 
with bone metastasis and improved the quality of life of patients (27, 115). It must be noted, 
however, that any differences observed in overall survival were marginal at best, suggesting 
that bone metastatic tumor cells can find alternative means of survival even without the aid of 
osteoclasts (116).  
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Figure 11. Therapies against bone metastasis target the cells of the bone 
microenvironment, not the cancer cells. Illustrated here is the vicious cycle of bone 
metastasis and the steps of the process targeted by bone metastasis-targeted therapy. Left: 
RANKL secreted by osteoblasts in response to stimulation by chemokines released from cancer 
cells causes the maturation of osteoclasts, which degrade the bone matrix. Denosumab acts 
as an antibody against RANKL, thereby decreasing osteoclast activity. Center: 
bisphosphonates act by inhibiting tumor cell adhesion to bone as well as directly enhancing 
osteoclast apoptosis. Right: dasatinib is a small molecule inhibitor of SRC, which is key to 
osteoclast proliferation and activity. Dasatinib may act through direct inhibition of cancer cells 
or osteoclasts. Reprinted with permission from Fornier MN. “Denosumab: second chapter in 
controlling bone metastases or a new book?” Journal of Clinical Oncology. 2010 Dec 
10;28(35):5127-31. 
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Recent breakthroughs in the technical ability to perform single-cell sequencing have 
shed more light on the nature of metastasis by enabling modeling of the evolutionary nature of 
metastasis. While population-level tumor genomic and transcriptomic profiling allowed 
researchers to see that indeed primary tumors and metastatic tumors are different in terms of 
overall gene expression (104, 105), they were unable to definitively provide answers to 
questions on the nature of metastasis that have been debated for many years (117). Namely, 
the questions of whether metastasis is a late-arising event in the natural history of a primary 
tumor (following the linear progression/Vogelgram model of step-by-step acquisition of required 
phenotypic traits) or dissemination occurs early in the evolutionary course of tumor 
development followed by a period of dormancy or microenvironmental adaptation (parallel 
progression). In experimental systems the answer has appeared to be more of the linear 
progression model, as metastatic subclones increase within cancer cell lines (41) and can be 
phenotypically selected in vivo for increased metastasis-forming capability (118, 119); however, 
the possibility exists that this observation may be somewhat affected by the experimental 
systems used (120). Single-cell sequencing has added the ability to interrogate the 
accumulations of mutations over time and in space, as comparing individual cells within a 
metastasis as well as between cells of different metastases and cells from metastases to cells 
from primary tumors are all possible. These analyses have allowed direct observation of the 
phenomenon reported by Fidler (41) that metastasis can result from the selection of pre-existing 
subclones within a primary tumor and have served to strengthen the linear progression model 
of metastasis (121-123). Nonetheless, tumor growth rate kinetic models lend support to the 
idea of parallel progression (91, 124), as do clinical observations. Even in women diagnosed 
with breast tumors less than 1 cm in diameter, node-negative, and metastasis-negative 
(T1a,bN0M0) who undergo a mastectomy, dissemination may have already occurred by the 
time of diagnosis, as there exists a 2% chance of breast cancer-specific mortality at 5 years 
and a 5% chance at 10 years (125). Another study showed the probability of distant recurrence 
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in 171 patients diagnosed with T1a,bN0M0 breast cancer and treated with mastectomy to be 
4% (126). Further support for the parallel progression model comes from pancreatic cancer, 
where clinical data has revealed early dissemination events (127) and experimental data has 
shown that dissemination can shockingly precede overt primary cancer detection (128). Finally, 
the existence of the clinical phenomenon of ‘cancer of unknown primary’ (CUP) serves to 
bolster the parallel progression model, as in 3-5% of metastatic adenocarcinomas, a primary 
tumor is unable to be identified, even at autopsy (129). In light of the available data, it would 
seem most likely that the process of metastasis follows a hybrid of the linear/parallel 
progression models (130), with metastasis initiated by dissemination of rare clones from within 
the primary tumor, but with the acquisition of additional phenotypic traits upon reaching the 
secondary site. The influence of the microenvironment on disseminated cancer cells should not 
be understated, as the metastatic potential of cancer cells can be reversibly altered by 
epigenetic modification (59, 131); this reversible modification can occur upon arrival at a 
secondary site and before metastatic outgrowth (132). 
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Figure 12. Metastasis arises from clonal populations of cells within the primary tumor. 
These clonal populations can represent either major (Metastasis 1) or minor (Metastasis 2) 
populations of cells within the primary tumor, and further evolution occurs following the 
dissemination of cancer cells, resulting in metastasis that are distinct from their associated 
primary tumors. Reprinted with permission from Caldas C. “Cancer sequencing unravels clonal 
evolution.” Nature Biotechnology. 2012 May;30(5):408-10. 
 
 In light of the highly selective nature of the metastatic cascade, with each step 
representing a potential barrier to success, it may serve as a useful reminder to consider those 
conditions necessary for evolution by natural selection to occur. First, within a population there 
must be some degree of phenotypic diversity. Second, members of a population must be able 
to reproduce and pass down these heritable differences. Last, there must exist some limit to 
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the ecosystem such that there is competition for finite resources (133). In the process of 
metastasis all of these conditions are fulfilled, as cancer’s tremendous genomic instability and 
biological heterogeneity lead to variation within a tumor (134), cell proliferation allows the 
creation of daughter cells resembling their parent cell, and there is a finite limitation of 
resources, both nutritional and volumetric, as both are limited within a tumor and within 
secondary organ sites. Therefore, cancer metastasis is clearly an example of evolution; might 
co-option of some evolutionary principles serve to enable both a better understanding of 
metastasis and a better chance for successful intervention in the process (134)? One aspect 
ripe for such examination is the stepwise nature of the metastatic cascade, which creates an 
evolutionary scenario replete with population bottlenecks. Indeed, through single-cell genomic 
analysis, it is possible to observe the results of such bottlenecks, as tumor cells with given 
genomic patterns within the primary tumor drop out of populations observed in metastases (see 
Figure 12 above) (121-123). These genomic observations represent strong evidence for the 
selective nature of metastasis; but since natural selection works on the phenotypic level, 
additional buttressing would come from evidence of enhanced abilities to perform functions 
required for metastasis. Unfortunately, most modeling of the steps of metastasis is performed 
in vitro (135, 136), leading to questions about the relevance or requirements of certain findings. 
However, with the falling costs of sequencing (137), it is now possible to interrogate specific 
aspects of the metastatic cascade in vivo at the single-cell level (138). For now, the best 
examples of matching of genotype to phenotype in cancer progression come from the 
population bottlenecks generated by drug treatment. Due to the genomic instability of cancer 
cells, development of resistance to chemo- or targeted therapies is inevitable, as minor 
subpopulations of cells exist pre-treatment with mutations that confer drug resistance. Following 
development of resistance in the clinic (e.g., tumor progression while the patient is still receiving 
therapy), it is possible to observe an increase in the allelic frequency of certain mutations; these 
mutations may be in the genes coding the drug targets themselves or in other pathways 
33 
 
involving drug efflux or apoptosis resistance (139-142). Recalling the principles of evolution, 
organisms (or cells) with differential fitness in a given environment will be more evolutionarily 
successful, i.e., become a more dominant population in successive generations. However, in a 
closed system, the expression of new phenotypes is never free; acquisition of new traits 
requires evolutionary tradeoffs. In this case of drug resistance this can come in the form of 
adenosine triphosphate (ATP) costs to maintain drug efflux pumps; with up to 33% of cellular 
ATP being spent on drug efflux, therapy-resistant cells will proliferate more slowly (143). The 
concept of exploiting evolutionary tradeoffs has been proposed for application to treatment of 
metastasis (144, 145); by identifying the Achilles’ heel exposed by high evolutionary costs at 
steps during metastasis, it may be possible to use combination therapy to produce an 
evolutionary double bind, a situation in which a metastasis is forced to fight a war on two fronts. 
A depiction of such a therapy is shown below in Fig 13 (146). In this hypothetical situation, 
Treatment 1 is targeted against one phenotype is to control a cancer population; the 
development of resistance to that therapy incurs an evolutionary cost that can be exploited by 
Treatment 2. However, as metastases are resistant to conventional therapies (111), intensive 
and careful study is required in order to expose these potential targetable tradeoffs. Even 
though metastasis represents evolutionary champions that are living in a state of cellular 
anarchy, identification of the molecular details of non-negotiable convergent evolutionary 
phenotypes that allow them to complete the metastatic cascade may enable identification of 
double bind scenarios.     
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Figure 13. Targeting evolutionary double binds for therapy against metastasis. Top graph 
shows alternating appearance of populations resistant to Treatment 1 and sensitive to 
Treatment 2, and vice versa. As resistance phenotype develops to one drug, remaining cells 
incur evolutionary cost that is exploited by second treatment. Alternation of therapy can 
continue over time. Bottom graph shows overall population density during alternating 
treatments, as tumor re-growth would indicate necessity of switching back to the alternate 
therapy. Modified and reprinted with permission from Enriquez-Navas PM, Wojtkowiak JW, & 
Gatenby RA. “Application of Evolutionary Principles to Cancer Therapy.” Cancer Research. 
2015 Nov 15;75(22):4675-80. 
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1.3 Brain metastasis 
1.3.1 Clinical overview of brain metastasis 
 In the United States, it is estimated that between 6% (147) and 14% (148) of all newly 
diagnosed cancers will ultimately metastasize to the brain; based on the 1.7 million new 
diagnoses of cancer expected in 2016 (1), between 100,000 and 240,000 cases can be 
expected to eventually metastasize to the brain. These numbers represent a conservative 
projection, for 3 major reasons: 1) autopsies of patients dying due to metastatic cancer are rare, 
making comprehensive studies difficult and meaning that the apparent numbers seen thus far 
may be a result of undersampling (149), 2) as improved systemic therapies have lengthened 
the survival of patients with metastases to other organs, they may go on to develop brain 
metastasis later (149), and 3) increased detection capability of clinical imaging modalities may 
allow for the identification of brain metastases that in prior years would have gone unnoticed 
(150). The primary cancers that most frequently metastasize to the brain are lung, breast, 
melanoma, and colorectal, accounting for ~45%, ~15%, ~10%, and ~5% of brain metastases, 
respectively. (149, 151) 
Once brain metastasis has occurred, the survival outcomes are dismal. Left untreated, 
the average survival is less than 2 months (152); palliative therapies including corticosteroids, 
chemotherapy, and radiotherapy can extend survival, in the best case, to an average of less 
than one year (153). When only a single brain metastatic tumor is detected, surgery or 
radiosurgery can be performed; however, the effect of these therapies on survival is still 
marginal, with life extended only a few months (151). Moreover, at the time of detection, multiple 
brain metastases are formed in more than 80% of patients, disallowing surgery as a therapeutic 
option (154, 155). As brain metastasis is almost universally chemoresistant, chemotherapy is 
usually only used for treating systemic (non-brain) metastasis growing synchronously with the 
brain metastasis or as salvage therapy (156, 157). Some primary tumors or tumor subtypes are 
more responsive to therapy targeting specific molecular or functional pathways; while patients 
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with known brain metastasis are typically excluded from trials for new agents, the enrollment of 
some patients admitted to trials before diagnosis of brain metastasis has allowed on a small 
window into the potential of targeted agents in brain metastasis, and it is generally not promising 
(158). While some targeted therapies do indeed show brain activity and successfully make it 
into the tumors, they are generally at lower concentrations than outside the brain (159), raising 
the question of whether efficacious concentrations of the drugs are reached or maintained. 
Further, these targeted therapies are designed against driver mutations in the primary tumors; 
it is unclear how necessary they are for the biology of brain metastasis. What is unique about 
the biology of the brain that makes for such a dismal prognosis in the setting of brain 
metastasis? 
 
 
Figure 14. Brain metastasis usually presents as multiple metastases. Magnetic resonance 
imaging (MRI) showing numerous metastatic lesions throughout the cerebrum and cerebellum 
of a woman with HER2-positive primary breast cancer. Reprinted with permission from 
Ammannagari N, Ahmed S, Patel A, & Bravin EN. “Radiological response of brain metastases 
to novel tyrosine kinase inhibitor lapatinib.” QJM. 2013 Sep;106(9):869-70. 
  
1.3.2 Brain as a unique microenvironment for metastasis 
 The specialization of the brain to suit its functions as the processing and control center 
for the body has led to the evolution of a number of features and safeguards not seen elsewhere 
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in the body. As the primary role of the brain is to house and support the neurons that allow for 
signals to be transmitted to and received from throughout the body, many of these features are 
specifically designed to support and maintain neuronal function and integrity. The unique nature 
of the brain microenvironment extends to its resident cell populations, structural composition, 
blood flow, and nutrient availability. Each of these special characteristics represents a potential 
challenge to would-be metastatic tumor cells; at the same time, cancer cells with the right 
features to survive in such an environment can take advantage of the neuroprotective 
environment in order to gain a foothold that has proven difficult to broach by current therapies. 
When speaking of cancer, the most frequently cited brain-specific feature is the 
presence of a blood-brain barrier (BBB) that separates the brain from the general circulation 
(160). This ‘barrier’ is in reference to both form and function, as cells and molecules are 
excluded from entry by physical obstruction, with the endothelial cells of the brain joined by tight 
junctions, as well as by active efflux through transporters. The main purpose of this barrier is 
the maintenance of homeostatic environment for neuronal function (161). Tight junctions, which 
are composed of proteins including claudins, occludins, and zona occludens (ZO) proteins 
(162), possess high electrical resistance (163), are surrounded by a thick basement membrane, 
and supported on the brain-facing side of the BBB by pericytes. The high electrical resistance 
prevents free diffusion of charged molecules through the BBB, while pericytes physically 
support endothelial cells and promote their survival and maturation (164). Finally, astrocytic 
endfeet form the final layer of the BBB. They express glucose transporters for allowing glucose 
into the brain and P-glycoprotein for pumping drugs/neuroactive compounds out of the brain, 
and can alter the tightness of the BBB in response to stresses such as hypoxia (165). Oxygen 
and other lipophilic molecules can directly diffuse into the brain through the endothelial cell 
membrane, and the brain’s high demand for oxygen means that at steady-state levels, the 
partial pressure of oxygen (pO2) in the brain is only 35 mmHg (equates to 4.6% oxygen), which 
maintains a continuous gradient of oxygen into the brain (166). Other required components of 
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brain function, such as amino acids, are selectively admitted to the brain by specialized 
transporters (167).  
 
Figure 15. The BBB is formed by specialized cell types in the brain acting in concert. 
Depicted here is a model of the BBB show its composition by different cell types. The inner 
lumen (white) is formed by the endothelial cells (red), which are connected by tight junctions. 
Pericytes (purple) partially cover the abluminal surface of the endothelial cells, which are 
surrounded by a thick basement membrane (red dotted line). The entire unit is encircled by 
astrocytes (blue); their endfeet express high levels of P-glycoprotein (as do endothelial cells 
themselves) and actively exclude most drugs crossing into the brain. Most compounds making 
it through the BBB are highly lipophilic, allowing them to diffuse across the endothelial cell 
membrane into the brain. Modified and reprinted with permission from Steeg PS, Camphausen 
KA, Smith QR. “Brain metastases as preventive and therapeutic targets.” Nature Reviews 
Cancer. 2011 May;11(5):352-63. 
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As cancer cells arrive and arrest in the vasculature of the brain, the first brain-specific 
challenge that they encounter is the BBB. An intact physiological BBB prevents the entry of 
cells into the brain; cells extravasating into the brain would therefore need to pass through the 
endothelial cell layer either paracellularly (between the cells, through the tight junctions) or 
transcellularly (through the endothelial cells themselves). While transcellular migration has 
been observed in immune cell extravasation, only paracellular migration has been detected in 
metastasis (168). Because tight junctions are composed of a variety of proteins, cancer cells 
would need to be able to express several proteases in order to penetrate intact tight junctions 
(169). Alternatively, these junctions can be destabilized by a variety of cytokines, chemokines, 
and inflammatory mediators frequently expressed by cancer, including VEGF, basic fibroblast 
growth factor (bFGF), transforming growth factor–β (TGF-β), interleukin-1β (IL-1β),TNF-α, 
interferon-γ (IFN-γ ), CCL2, CXCL8, prostaglandin-endoperoxide synthase 2 (COX2),  (79, 87, 
88, 170); cancer cells can then secrete MMPs and other proteases in order to disrupt the BM, 
as in metastasis to other sites. (87, 171).  
After bypassing the BBB, cancer cells still have to cope with the unique nutrient 
composition of the brain. Part of this challenge involves obtaining sufficient oxygen in a tissue 
with a low pO2, where there is a high degree of competition from neurons. Neurons solve the 
problem of maintaining enough oxygen for mitochondrial respiration by never being farther than 
40µm away from the nearest capillary (172); cancer cells in the brain converge upon this 
phenotype as well, as imaging studies on experimental brain metastasis showed that cancer 
cells stay in contact with blood vessels even following extravasation, until either VEGF-A-
mediated neoangiogenesis occurs or, more frequently in brain metastasis, the vasculature is 
remodeled and co-opted by the cancer cells (75). One of the controversies in the field of brain 
metastasis is the degree to which the BBB is disrupted following brain metastasis outgrowth. 
While some studies have detected a heterogeneous permeability to chemotherapeutic agents 
by brain metastases (173), others have shown that effects of brain metastasis on the leakiness 
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of the BBB are cell line-dependent, with examples of both intact (174) or disrupted (175) BBB 
in different contexts. In either case, this distinction is more than academic; if the BBB is not 
functioning effectively around brain metastases, it might allow for delivery of efficacious doses 
of therapeutics to brain tumors. Frustratingly, even in advanced brain metastases in which a 
loss of functional integrity of the BBB would be expected, especially when metastases perform 
vascular remodeling or neoangiogenesis (75, 176), the accumulation of a wide variety of 
chemotherapeutic and small molecule targeted therapies still occurs at sub-optimal levels 
(177). 
A better explanation for therapeutic resistance of brain metastasis may lie not in the 
hijacking of the brain’s vasculature by brain metastases, but in the co-option of astrocytes, the 
brain’s essential support cells. Astrocytes in the physiological brain serve homeostatic functions 
in support of the BBB (178, 179) as well as signaling and delivering nutrients directly to neurons 
(180). Astrocytes’ homeostatic functions include prevention of cellular invasion of the brain 
parenchyma; cancer cells breaching the BBB are soon met by astrocytes that release Fas 
ligand (FasL) to trigger cancer cell apoptosis (181). Successful brain metastases win this 
molecular arms race by expressing serpins, which prevent astrocytic release of FasL. After 
evading elimination by astrocytes, cancer cells can take advantage of the protective benefits 
that astrocytes usually afford neurons by a variety of mechanisms. Through gap junction 
communication, astrocytes upregulate survival genes in brain metastatic cells, promoting 
chemoresistance (182). This effect involves the engagement and upregulation of the endothelin 
axis (112); antagonism of the endothelin axis chemosensitized tumor cells and significantly 
extended survival in models experimental brain metastasis of lung and breast cancer (183). In 
addition to gap junction communication, brain metastases can activate the pro-growth/survival 
effects of astrocytes by secretion of IL-1β (184) or CCL2 (132), and have even been shown to 
enhance the differentiation of neural progenitor cells into astrocytes (185). 
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On top of oxygen availability, the limited availability of nutrients in the brain makes for a 
significant evolutionary bottleneck in the pathogenesis of brain metastasis. As the BBB 
excludes most molecules from simply diffusing into the brain, specialized transporters are 
necessary for their entry. These transporters exist for the import of glucose and some amino 
acids; the high capacity of the endothelial cells glucose transporter GLUT-1 of 1420 nmol/min 
x g tissue ensures the continuous import of glucose into the brain (186). The availability of 
glucose, inability of other metabolic substrates, and high energy demands of the brain together 
results in the brain’s utilization of 20% of the body’s glucose (187), which is evident by the 
intense background signal of the brain in 18F-deoxyglucose (18-FDG) positron emission 
tomography (27) (27) imaging (188). Astrocytes and neurons can both utilize glucose that 
makes it into the brain, astrocytes through GLUT-1 and neurons through GLUT-3, which has a 
higher glucose affinity (189). Once inside the cell, glucose can be used for either ATP synthesis 
or the generation of other biomolecules. In either event, the first step of glucose metabolism is 
the phosphorylation of glucose by hexokinase, generating glucose-6-phosphate (190). At this 
point, the glucose-6-phosphate can either continue down the glycolysis pathway and be used 
for ATP generation, or be shunted into the pentose phosphate pathway in order to  generate 
NADPH be used for the production of other biomolecules (190). Brain metastasis has been 
observed to utilize both glycolysis and the pentose phosphate pathway. A study of human 
breast cancer brain metastases, which at least in their early stages of colonization are still 
restricted by a functional BBB, showed that the gene most highly upregulated relative to 
unmatched primary tumors was  hexokinase 2 (HK2), showing the importance of glycolysis for 
intracerebral tumor growth and survival (191). A second study using experimental brain 
metastasis models showed enhanced utilization of glucose in both glycolytic and pentose 
phosphate pathways (192). That the same pathway was repeated by independent studies 
serves to demonstrate that the physiological constraints imposed by the brain must be 
overcome in order for successful metastasis. 
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While it has been widely reported that due to the BBB, amino acids exist at lower levels 
in the brain than the plasma, literature reports quantifying this phenomenon are scarce. Further, 
the presence of the large neutral amino acid transporter 1 (LAT1) system enables the facilitated 
diffusion of some amino acids (193), so quantification of the true concentration of amino acids 
available to cells in the brain would be ideal. While these data are not available, an Alzheimer’s 
disease study from 1990 did examine the cerebrospinal fluid (CSF) content of amino acids. 
Comparison of the amino acid content in plasma and CSF of the healthy volunteers of that 
study (n=11) was performed in Table 3, and revealed that the only amino acid found at 
comparable levels in the general circulation and the CSF is glutamine, an important precursor 
of the neurotransmitters glutamate and γ-aminobutyric acid (GABA) (194). This is suggestive 
that utilization of glutamine may be an important functional constraint on successful brain 
metastasis growth. 
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Table 3. Amino acid content of human cerebrospinal fluid (CSF) and plasma. 
Amino acid CSF concentration (μM) Plasma concentration (μM) CSF/plasma ratio 
Glutamic acid 42 62 0.68 
Glutamine 505 500 1.01 
Taurine 9 77 0.12 
Alanine 34 319 0.11 
Glycine 21 225 0.09 
Isoleucine 5 58 0.09 
Leucine 14 119 0.12 
Methionine 5 22 0.23 
Phenylalanine 9 54 0.17 
Serine 30 109 0.28 
Threonine 32 110 0.29 
Tryptophan 0 41 0 
Tyrosine 14 64 0.22 
Valine 20 233 0.09 
Arginine 23 87 0.26 
Histidine 20 88 0.23 
Lysine 25 181 0.14 
Ornithine 7 69 0.1 
The concentrations of amino acids in the CSF or plasma of healthy human volunteers are 
shown. Most amino acids are relatively scarce in the brain, with the lone exception being 
glutamine, which is found at levels equal to its plasma concentration. Table modified and 
reprinted with permission from Basun H, Forssell LG, Almkvist O, Cowburn RF, Eklöf R, 
Winblad B, & Wetterberg L. “Amino acid concentrations in cerebrospinal fluid and plasma in 
Alzheimer's disease and healthy control subjects.” J Neural Transm Park Dis Dement Sect. 
1990;2(4):295-304. 
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 In general, glutamine metabolism in the brain occurs in the form of a cycle rather than 
as a unidirectional catabolic process. This series of reactions is known as the glutamine-
glutamate cycle, and it is responsible for maintaining the supply of the neurotransmitter 
glutamate while also preventing constitutive neuronal hyperpolarization. Since glutamate can 
be converted into glutamine, which is non-neuroactive, glutamine is the preferred form of the 
compound when in the brain. The glutamine-glutamate cycle occurs when glutamate is 
released into a glutamatergic synapse by the pre-synaptic neuron. Some glutamate binds to its 
receptors on the post-synaptic neuron, but there is excess synaptic glutamate. This glutamate 
is taken up by the surrounding astrocytes, which express high levels of excitatory amino acid 
transporters (EAATs). Inside the astrocytes, the glutamate is metabolized by glutamine 
synthetase, and processed into glutamine by the addition of an amino group. This glutamine is 
then released by the astrocytes and taken up by pre-synaptic neurons. It is within pre-synaptic 
neurons that glutaminolysis occurs, with glutaminase breaking down glutamine into its 
constituents glutamate and ammonia. The newly synthesized glutamate is then packaged into 
vesicles and released into the synapse, and the cycle proceeds again. Notably, cancers and 
cancer cell lines have exhibited the potential to participate in the glutamine-glutamate cycle, 
demonstrating a similar phenotype as neurons, with uptake of glutamine and release of 
glutamate (195-198). 
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Figure 16. The glutamine-glutamate cycle. Glutamine and glutamate are both present and 
continuously being exchanged in normal brain physiology. Glutamate-containing vesicles within 
the presynaptic neuron (blue) fuse to the neuronal cell membrane and are released into the 
synapse. Some of this glutamate binds to glutamate receptors (mGluR, NMDAR, or AMPAR) 
on the post-synaptic neuron (purple); the remainder is taken up by neighboring astrocytes via 
their excitatory amino acid transporters (EAATs) in order to prevent neuronal hyperpolarization. 
Within the astrocyte, glutamine synthetase converts ammonia and glutamate into glutamine, 
which is then transported to the pre-synaptic neuron. Within the neuron, then glutamine is 
converted to glutamate and the process is repeated. Modified and reprinted with permission 
from Popoli M, Yan Z, McEwen BS, & Sanacora G. “The stressed synapse: the impact of stress 
and glucocorticoids on glutamate transmission.” Nature Reviews Neuroscience. 2012 
Jan;13(1):22-37  
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Moreover, both brain metastasis and primary tumors have previously been reported to 
exhibit altered glutamine metabolism (199). Specifically, they have both been shown to possess 
an enhanced ability to utilize glutamine as both an energy source and as a precursor to cellular 
building blocks, including purines, pyrimidines, and non-essential amino acids (200-
202).  However, it remains unknown whether brain metastatic cells possess an intrinsic ability 
to better utilize glutamine, or if this phenotype arises out of selection by the brain environment. 
Finally, a mechanistic understanding of the regulation and cause of this enhanced glutamine 
utilization is lacking, meaning that although the phenotype is biologically important and serves 
as an evolutionary bottleneck for metastatic growth in the brain, it cannot currently serve as a 
therapeutic target.  
 
1.4 Hypothesis and specific aims 
 Brain metastasis represents an incredibly selective process that few cancer cells have 
the capability of performing. While prior studies have focused on those genes that are most 
differentially expressed between brain and non-brain metastases or between brain metastases 
and primary tumors, here I propose that kinases may enhance key phenotypes that promote 
brain metastasis growth. Identification of such kinases could elucidate the functional restraints 
placed on metastatic cells arriving in the brain and potentially identify new avenues of 
intervention. 
To test this hypothesis, I propose the following two specific aims: 
Aim 1: perform an in vivo functional genomics screen to identify kinases potentially 
promoting the growth and formation of breast cancer brain metastasis. 
 
Aim 2: Validate the top potential hit from this screen as functionally important in the 
process of brain metastasis. 
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Chapter 2: Materials and Methods 
Kinase library preparation 
The kinase open reading frame (ORF) library used to perform the in vivo kinome screen 
was an expanded version of the library used in (203), containing 353 ORFs compared to 258 
ORFS in the original library. The ORFs were contained in the retroviral vector pWZL-Neo-Myr-
Flag DEST, allowing expression of ORF sequences under control of the CMV promoter and 
stable selection in target cells by G418.  
 
Figure 17. Kinase ORF library is expressed in the pWZL-Neo-Myr-Flag-DEST retroviral 
vector. Expression clones were generated by Gateway LR reactions, which inserted single 
kinase sequences between the attR1 sites. Reprinted from Addgene. 
 
In order to express the ORFs in a pooled format, five 96-well plates containing glycerol 
stocks of the ORFs were divided into quadrants of 24 wells. Five microliters of each glycerol 
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stock was inoculated into 3 mL of LB broth containing 100 µg/mL carbenicillin and grown at 
37°C in a Forma Orbital Shaker (Thermo Fisher) at 250 rpm overnight. The following day, pools 
of ORF clones were generated by combining groups of 24 clones, with each pool representing 
one quadrant of each kinase library plate. Inoculum from each ORF clone (1 mL per clone; 24 
mL per pool) was added to fresh LB media containing 100 µg/mL carbenicillin for a total volume 
of 100 mL and grown for an additional 4 hours. Following this 4 hour growth period, the 
inoculated LB broth for each pool was centrifuged at 4000 x g for 10 minutes at 4°C. Plasmid 
DNA was isolated using a Qiagen Maxiprep kit according to the manufacturer’s protocol and 
quantified using a NanoDrop ND-1000 spectrophotometer. 
 
Cell lines and cell culture 
 Cell lines were cultured and maintained in Dulbecco's Modified Eagle Medium-Ham’s 
Nutrient Mixture F-12 (DMEM/F12), which contains 17.5 mM glucose and 2 mM glutamine, 
supplemented with 10% fetal bovine serum (FBS) and 100U/mL penicillin/streptomycin (Gibco). 
Cells were regularly tested for mycoplasma contamination using the MycoAlert Mycoplasma 
Detection Kit (Lonza). For later experiments involving Basal Medium Eagle (BME), cells were 
cultured in BME, which contains 5.56 mM glucose, supplemented with 5% dialyzed FBS. The 
amount of glutamine added varied by experiment. Cell lines used were obtained from American 
Type Culture Collection (ATCC), and included Phoenix-AMPHO, MDA-MB-231, HCC1954, and 
HEK293T. MDA-MB-231.TdTomato (231.TdTomato) and MDA-MB-231.luciferase.GFP 
(231.luc.GFP) were generated by Gateway cloning and lentiviral transduction, followed by 
fluorescence-associated cell sorting (FACS) for selection of fluorescent-positive cells.  
 
Fluorescence-associated cell sorting (FACS) 
 FACS was performed in the Flow Cytometry and Cellular Imaging Core (UTMDACC) on 
a Becton Dickinson FACS Aria II. Following trypsinization, cells were filtered through 35 μm cell 
strainers into a 5 mL Falcon tube (Corning) to ensure a single cell suspension. Cells were 
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analyzed on the FACS Aria II using the FITC and PE channels for 231.luc.GFP and 
231.TdTomato cells, respectively; non-fluorescently labeled cells served as a negative control. 
The top 10% of fluorescent cells were collected and cultured in 200U/mL penicillin/streptomycin 
to eliminate any potential contamination acquired during FACS. Stably transfected target cells 
were frozen in aliquots at low passage number. 
 
Retroviral transfection 
 For retroviral production, the amphotropic Phoenix cell line (ATCC) was used. Phoenix 
cells are derived from the HEK293T cell line and allow for packaging plasmid-free retroviral 
production, due to gag-pol and viral envelope protein expression (204). Briefly, wells of a 6-well 
plate were pre-coated with poly-L-lysine, following by the addition of 2.5 x 105 Phoenix cells to 
each well for a confluency of approximately 70% the following day.  Prior to transfection, media 
was replaced with 1 mL of DMEM/F12 containing FBS. Separate dilutions of 1 µg plasmid DNA 
and µL LipoD293 reagent (Signagen) were made in serum-free DMEM/F12 and mixed via 
pipetting, according to the manufacturer’s protocol. LipoD293 reagent was then added to the 
plasmid DNA and vortex-mixed. The liposomal-plasmid DNA mixture was allowed to incubate 
at RT for 15 minutes, and then added drop-wise to the Phoenix cells. After 18 hours, 1.5 mL of 
DMEM/F12 media with 10% FBS was added to each well. Two days post-transfection, the 
retrovirus-containing media was aspirated into a 10 cc syringe fitted with an 18-gauge needle 
and filtered through a 0.45 µm filter to remove Phoenix cell debris. Target cells were plated at 
10% confluency in 6-well plates the day before virus collection, so that at the time of retroviral 
infection they were 20% confluent. The virus-containing media, which totaled 2 mL due to 
evaporation and dead volume in the syringe and filter, was added to target cells along with 8 
mL of fresh DMEM/F12 with 10% FBS and 10 µL of 5 µg/mL polybrene. After 48 hours of 
infection and expansion, G418 was added to the target cells to select for plasmid expression.  
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Lentiviral transfection 
Lentiviral transfection was performed similarly to retroviral transfection, except 
HEK293T cells (293T) were used to produce lentivirus. Since 293T cells do not contain 
packaging or envelope plasmids, exogenous packaging plasmid DNA (psPAX2 [Addgene 
plasmid # 12260], gift from Didier Trono) and envelope plasmid DNA (pMD2.G [Addgene 
plasmid # 12259], gift from Didier Trono) was included at the time of liposomal-DNA complex 
formation, in a ratio of 4:3:1 (target DNA:psPAX2:pMD2.G). Additionally, as active cell division 
is dispensable for lentiviral DNA to integrate into the cellular genome, the target cells were 
plated at 25% confluence and were approaching 50% confluence on the day of infection.    
 
Intracarotid injection 
All animal procedures were approved by the UTMDACC Institutional Animal Care and 
Usage Committee (IACUC). Accordingly, animals received humane care as per the Animal 
Welfare Act and the NIH "Guide for the Care and Use of Laboratory Animals." For intracarotid 
injection, 8-week-old female Swiss nude mice were purchased from the Department of 
Experimental Radiation Oncology at UTMDACC. Mice were anesthetized with ketamine (90 
mg/kg body weight) and xylazine (10 mg/kg body weight) and restrained supine on a glass 
board. Their heads were secured to the board by placing a rubber band placed around the teeth 
of the upper jaw. The surgical site was disinfected with Betadine and 70% ethanol, and a 1 cm 
incision made slightly left of the midline, starting from the first mammary gland up into the neck 
area. The trachea was then exposed by blunt dissection. Under a dissecting microscope, the 
thin layer muscle was dissected in the carotid muscular triangle to expose the right common 
carotid artery. The artery was then separated from the vagal nerve and jugular vein. A 5-0 silk 
suture was placed under the proximal part of the common carotid artery and tied tightly to 
prevent blood flow from the heart to the injection site. A second ligature was then placed under 
the common carotid artery distal to the expected injection site and tied loosely. A 3-4 mm sterile 
cotton ball was briefly soaked in Hank’s Buffered Saline Solution (HBSS) for lubrication and 
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then placed under the artery between the two sutures to elevate the common carotid artery in 
order to control the blood regurgitation from the distal part. Cell suspensions (100 μL of cancer 
cells in HBSS) were drawn into a 1-cc insulin syringe without the formation or presence of 
bubbles. Cells were then injected slowly and the needle retracted. The second ligature distal to 
the injection site was quickly tied to prevent leakage of the injected cells, and the ends of the 
silk ligatures trimmed. The skin of the surgical site was then stapled together and the animals 
given subcutaneous buprenorphine to relieve pain. The animals were placed on a reusable 
chemical heating pad until they regained consciousness. At the endpoint of the experiment, 
mice were euthanized according to IACUC guidelines by CO2 asphyxiation followed by cervical 
dislocation. 
 
Mammary fat pad injections 
 For mammary fat pad injections, 8-week-old female Swiss nude mice were purchased 
from the Department of Experimental Radiation Oncology at UTMDACC. Cancer cells were 
prepared at 2x the intended injection concentration in HBSS, and then diluted 50:50 with 
Matrigel and placed on ice. Mice were anesthetized with ketamine (90 mg/kg body weight) and 
xylazine (10 mg/kg body weight). The cells were injected into the #3 mammary fat pads using 
a 25G needle without incision. Injection efficiency was measured the day after injection using 
in vivo imaging system (IVIS) analysis. At the endpoint of the experiment, mice were euthanized 
according to IACUC guidelines by CO2 asphyxiation followed by cervical dislocation. 
 
In vivo imaging system (IVIS) analysis 
 Luciferase-labeled tumor cell growth was monitored in vivo by IVIS. Imaging was 
performed in the Small Animal Imaging Facility of UTMDACC on an IVIS-200 (Xenogen). Prior 
to imaging, mice were injected intraperitoneally with 100 µL of D-luciferin potassium salt 
(Biosynth) diluted at 15 mg/mL in phosphate-buffered saline (PBS) and anesthetized by 
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isoflurane/O2 5 minutes after D-luciferin injection. Luminescent images of tumor cells were 
captured using the Living Image 3.2 software. 
 
Recovery of cancer cells from in vivo tumors 
For recovery of cells from in vivo brain metastases, tumor cells had to be harvested from 
the brains of metastasis-bearing animals. Briefly, following euthanasia of a brain metastasis-
bearing mouse, the brain was placed in a petri dish on ice. A 10 cm cell culture dish was pre-
coated by briefly rinsing with poly-L-lysine to support cell attachment, and a 100 μm cell strainer 
placed in the dish with 5 mL complete media with 200U/mL penicillin/streptomycin. Forceps 
were used to place the brain in the cell strainer, and the brain was homogenized using the 
plunger of a 5 mL syringe, rinsing the strainer periodically with 1 mL of complete media with 
200U/mL penicillin/streptomycin (up to 10 mL total) until the strainer was mostly cleared. The 
brain homogenate was then cultured overnight at 37°C. The following day, the supernatant was 
removed and added to a second poly-L-lysine coated dish, and fresh media with antibiotics was 
added to the original dish. After 1-3 days, tumor cell colonies were visible through the floating 
brain debris. Once colonies were numerous but still relatively low confluency, both primary and 
secondary plates were trypsinized and combined into single 15 cm dish with normal cell culture 
media. As cells approached 90% confluency, they were aliquoted and either frozen as a newly 
established Br subline (HCC1954Br) or used for genomic DNA extraction in the kinase library 
screen. 
 
RNA isolation 
Total RNA was isolated from cells or tissues using RNAzol RT (Molecular Research 
Center, Inc.) according to manufacturer’s instructions. For direct RNA isolation from tissues, 
brain were minced by with scalpels at time of animal sacrifice and stored at -80°C in RNA 
stabilizing agent RNAlater (Sigma-Aldrich) until time of RNA isolation. RNA was quantified 
using an ND-1000 spectrophotometer (NanoDrop). 
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Complementary DNA (cDNA) synthesis 
 cDNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-rad), according 
to manufacturer’s instructions. A mixture of random hexamers and oligo(dT) primers were used. 
 
Genomic DNA (gDNA) extraction 
 gDNA was isolated using the DNEasy Blood & Tissue kit (Qiagen), according to 
manufacturer’s instructions. DNEasy provides column and centrifugation-based DNA isolation. 
DNA was quantified using an ND-1000 spectrophotometer (NanoDrop). 
 
Polymerase chain reaction (PCR), Reverse transcriptase-PCR (RT-PCR), quantitative PCR 
(qPCR), and qRT-PCR 
 PCR to analyze DNA or gene expression of gDNA or cDNA was performed one of the 
following three ways: 
1. presence/absence analysis: PCR of gDNA or RT-PCR of cDNA was performed on a 
C1000 Touch thermal cycler (Bio-rad) using a Taq-based protocol. For kinase ORF PCR 
analysis, the optimal annealing temperature was determined to be 52° C and the 
extension time 4 minutes to accommodate the widest range of target sizes while 
maintaining the specificity. Custom primer pairs for analyzing the kinase ORFs were 
designed using VectorNTI software (Invitrogen) and ordered from Sigma and included 
NeoF (5’-GGATTGCACGCAGGTTCT-3’) and NeoR (5’-
GCTTCAGTGACAACGTCGAG-3’)  and KSPF (5’-CAAAGACGATGACGACAAGCA-3’) 
and KSPR (5’-CTTCCTTCACGACATTCAACAGA-3’). PCR products were analyzed on 
a standard 1% agarose DNA gel using ethidium bromide for ultraviolet (UV) 
visualization. 
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2. TaqMan: validated, human-specific, FAM-labeled TaqMan gene expression arrays were 
purchased from Thermo Fisher. Probes used were CDK16 (Hs00178837_m1), GLS 
(Hs00248163_m1), GLS2 (Hs00998733_m1), GFPT1 (Hs00899865_m1), and 18S-VIC 
(4310893E).  Due to its labeling with the fluorophore VIC instead of FAM, the primer 
assay against 18S ribosomal RNA (18S-VIC) could be included in each well as an 
internal control. qRT-PCR was performed on a StepOne Plus instrument (Applied 
Biosystems) using KAPA PROBE FAST reagents (KAPA). Results were analyzed using 
StepOne software and data were normalized to 18S signal. 
3. SYBR Green: the same primer pairs as in “presence/absence analysis” above were 
used. KAPA SYBR FAST reagents were used to perform qPCR on a StepOne Plus 
instrument. Cycle threshold (Ct) values were calculated for kinase ORF amplification 
and used to establish sample-specific PCR conditions required to obtain satisfactory 
quantities of DNA for sequencing. 
 
TOPO cloning 
 TOPO cloning was performed using a TOPO TA Cloning kit (Thermo Fisher), according 
to manufacturer’s instructions. PCR products with A-overhangs, resulting from Taq-based 
amplification, were subcloned into pCR-4-TOPO vectors and transformed into competent E. 
coli. Transformed E. coli were inoculated into LB media and minipreps (Qiagen) were 
performed. The resulting DNA was Sanger sequenced by the DNA Analysis Core (UTMDACC) 
from pCR-4-TOPO-specific primers M13F (5’-GTAAAACGACGGCCAG-3’) and M13R (5’-
TCACACAGGAAACAGCTATGAC-3’). The sequences were then analyzed by the National 
Library of Medicine’s Basic Local Alignment Search Tool (BLAST). 
 
shRNA 
 shRNA-encoding plasmids expressed in the lentiviral pGIPZ vector were obtained from 
the shRNA and ORFeome Core at UTMDACC, which distributes shRNA from GE-Dharmacon. 
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The shRNAs used to target PCTK1 were clones V2LHS_202028, V2LHS_59072, 
V3LHS_310893, V3LHS_310895, and V3LHS_310898, which are referred to ordinally as 
shPCTK1-1, shPCTK1-2, shPCTK1-3, shPCTK1-4, and shPCTK1-5 for the remainder of this 
dissertation. Stable vector-expressing cancer cells were selected both by puromycin resistance 
and FACS sorting for GFP positivity, as both selective markers are encoded by the vector. 
Knockdown efficiency was assayed at the RNA and protein levels by qRT-PCR and western 
blotting, respectively.   
 
Next-generation sequencing (NGS) of kinome screen samples 
 gDNA from tumor cells recovered from in vivo brain metastases was amplified by PCR 
using kinase vector-specific primers KSPF (5’-CAAAGACGATGACGACAAGCA-3’) and KSPR 
(5’-CTTCCTTCACGACATTCAACAGA-3’). The number of PCR cycles required to amplify the 
minimum amount of DNA required for NGS barcoding was empirically determined by SYBR 
Green-based qPCR. Following kinase vector-specific amplification, column-based purification 
of PCR products was performed using MinElute columns (Qiagen). DNA barcoding, adapter 
ligation, and library preparation were performed using the NEXTflex DNA Sequencing Kit (Bioo 
Scientific) according to the manufacturer’s instructions, with unique barcodes added to each in 
vivo sample. The resulting barcoded DNA libraries were analyzed by a MiSeq instrument 
(Illumina) using 150-base pair (bp), paired-end (PE) sequencing. Reads were normalized to the 
total total reads for each barcode, such that each in vivo sample had equal representation using 
MiSeq Reporter. Fastq files from Illumina paired-end sequencing were mapped to human 
transcriptome version hg19 using tophat2 (https://ccb.jhu.edu/software/tophat/ 
index.shtml).  Mapped reads were converted to bedGraph files using HOMER 
(http://homer.salk.edu/homer/).  For each kinase in each pool of the screen, the expression was 
estimated by collecting all bedGraph reads falling inside the gene boundaries (based on refseq 
gene definitions, available at http://hgdownload.soe.ucsc.edu/downloads.html). 
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RNA sequencing (RNA-seq) of human brain metastases 
 The RNA-seq data presented about gene expression within human brain metastases 
was obtained via a collaboration with Drs. Jodi Saunus and Sunil Lakhani at the University of 
Queensland, and the methods used for RNA-seq are published (205). Briefly, RNA-seq was 
performed on 32 human brain metastases. RNA was extracted from fresh-frozen brain 
metastasis surgical samples using the Qiagen AllPrep Kit, according to the manufacturer’s 
instructions, and quantified using a Bioanalyser (Agilent). From their publication: 
The protocol for Ribosomal depletion and RNA library construction was 
performed on 1 µg total RNA from each sample, using TruSeq Stranded Total RNA kit 
with Ribo-Zero Human/Mouse/Rat Set A (Illumina, cat. no. RS-122-2201). Libraries 
were prepared according to the manufacturer's protocol (TruSeq Stranded Total RNA 
Sample Prep Guide), with minor modifications to the fragmentation time (0 min 
fragmentation was used to increase the insert length). The libraries were quality 
checked and quantified using the Bioanalyser High Sensitivity DNA kit (Agilent). 
 All the RNA libraries were indexed, allowing multiplexed sequencing. Prior to on-
board cluster generation and sequencing run, the pooled library was denatured by using 
0.1 N NaOH and diluted to the required concentration (7 pM). Libraries were sequenced 
as 100 bp paired-end reads on the Illumina HiSeq 2000. RNA data were analysed using 
RSEM [7] and a normal expected count was used for expression values (using TMM 
normalization in the edgeR package), which was then transformed to normalized 
counts/million. 
 
From Saunus et al (2015), Integrated genomic and transcriptomic analysis of human brain 
metastases identifies alterations of potential clinical significance. J. Pathol., 237: 363–378. doi: 
10.1002/path.4583. Reprinted with permission 
 
Hard agar assay 
 In brief, 1 mL of DMEM containing 23% FBS and 0.6% agar (Lonza) was plated into 
individual wells of 24-well plates (BD Biosciences). Cancer cells were trypsinized and 
resuspended in DMEM containing 10% FBS. The resulting cell mixture was then passaged 
through a 40-μm cell strainer (BD Biosciences) to generate a single-cell suspension. Cells were 
resuspended at a density of 4000 cells/well in 1 mL of DMEM containing 23% FBS and 0.9% 
agar. This cell-containing mixture was then pipetted gently over the bottom layer of agar (0.6%) 
in the wells. The numbers and diameters of tumor colonies were calculated using a microscope 
when the tumor colonies became visible, and the experiment was terminated after 60 days.  
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Western blot analysis 
 Total cell lysates were obtained by resuspending cell pellets in immunoprecipitation (IP) 
lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 
2.5 mM sodium pyrophosphate, 1 mM beta-glycerolphosphate, 1 mM sodium orthovanadate, 1 
mM PMSF, and protease inhibitor cocktail). Following addition of lysis buffer, lysates were 
sonicated or passed through syringe with 22G needle 15 times followed by centrifugation. The 
supernatant was transferred to a new tube, and protein concentration was determined by BCA 
protein Assay Kit (Pierce), using known amounts of bovine serum albumin (BSA) to standardize 
protein concentration. Cell lysates containing equal amounts (20-40µg, depending on 
experiment) of protein were subjected to electrophoresis using sodium dodecosulfate-
polyacrylamide gel elecotrophoresis (SDS-PAGE) and transferred to polyvinyldifluoride (PVDF) 
membranes (Bio-Rad). PBS-Tween (PBST) was prepared as 0.1% (v/v) of Tween 20 in PBS. 
Membranes were blocked with 5% milk PBST for 30-60 minutes at room temperature, followed 
by primary antibody incubation overnight at 4°C. After three washes with PBST (5 minutes 
each), membranes were incubated with HRP-conjugated secondary antibody (in 5% milk in 
PBST) for 60 minutes at room temperature followed by three 5-minute washes with PBST, and 
signal was detected by enhanced chemiluminescence (ECL) (Amersham) per the 
manufacturer’s instructions. Antibodies used were PCTK1: rabbit anti-human CDK16, clone 
HPA001366 (Sigma) and mouse anti-β-actin, clone AC-74 (Sigma) 
 
Invasion 
 Transwell invasion assay was performed as previously described, with some 
modifications (206). 15 μL of Matrigel (Corning) diluted 1:4 in PBS was added to the top 
chamber of a 24-well transwell plate (Millipore). After Matrigel polymerization, the bottom 
chambers were filled with 600 µL DMEM/F12 medium containing 10% FBS. The top chambers 
were seeded with 5×104 cancer cells per well in 200 µL serum-free medium. After 24 hours, 
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the experiment was terminated by scraping remaining cells off of the top chamber with a cotton 
swab. Invaded cells were fixed in 4% paraformaldehyde and stained with 0.05% Crystal Violet. 
Images were taken using an Olympus digital microscope and invading cells were counted 
manually. The assays were performed in technical and biological triplicate. 
 
Migration 
 Transwell migration assay was performed as previously described, with some 
modifications (206). The top chambers of a 24-well transwell plate (Millipore) were seeded with 
3×104 cancer cells in 200 µL DMEM/F12 serum-free medium per well.  Then, 300 µL 
DMEM/F12 medium containing 10% FBS was added to the bottom chamber. After 18 hours, 
the experiment was terminated by scraping remaining cells off of the top chamber with a cotton 
swab. Migrated cells were fixed in 4% paraformaldehyde and stained with 0.05% Crystal Violet. 
Images were taken using an Olympus digital microscope and invading cells were counted 
manually. The assays were performed in technical and biological triplicate. 
 
Glutamine uptake and metabolite tracing/mass spectrometry (MS) 
 For experiments measuring rates of glutamine uptake and glutamate release over time, 
samples were analyzed on a 2900D Biochemistry Analyzer (YSI). MassLynx software version 
4.1 was used for data acquisition and analysis of glutamate and glutamine. Spectra of enriched 
peaks were compared against reference spectra. 
 
Immunohistochemistry (IHC) 
 IHC staining of PCTK1 on formalin-fixed, paraffin-embedded samples was performed 
using rabbit anti-human CDK16, clone HPA001366 (Sigma). Briefly, slides were 
deparaffinized by heating on a slide warmer for 20 minutes, followed by rehydration via a 
series of 3-minute wash steps. Slides were submerged in xylene 2x, 100% ethanol 2x, 90% 
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ethanol 1x, 80% ethanol 1x, and 70% ethanol 1x, and transferred to running water to rinse. 
Heat-induced antigen retrieval was then performed using sodium citrate buffer, pH 6.0, in a 
pressure cooker for 10 minutes. Blocking of non-specific epitope binding was achieved with 
Protein Block (Dako). Primary antibody incubation was performed overnight at 4°C, at an 
empirically determined dilution of 1:100 in Antibody Diluent (Dako). The next day, slides were 
incubated for 15 in 0.3% H2O2 in Tris-buffered saline (TBS) to quench their endogenous 
peroxidase activity. Secondary antibody staining was then performed using the Polink-2 HRP 
Plus Rabbit DAB system (GBI) according to manufacturer’s protocol, except TBS and TBS-
Tween (TBST) were used in place of PBS and PBST, respectively. Following secondary 
antibody incubation and chromogen development, slides were counterstained with 
hematoxylin, dehydrated, and mounted using organic mounting media. 
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Chapter 3: Kinome Screen 
To test whether heretofore unknown kinases may indeed be drivers of brain metastasis, 
we set out to perform an unbiased in vivo screen. MDA-MB-231 cells were selected as the cell 
background for this screen because they were originally derived from the pleural effusion of a 
patient with claudin-low TNBC, and TNBC has the highest relative rate of brain metastasis 
among breast cancer subtypes. First, pools of retroviral constructs were used to infect MDA-
MB-231.luciferase.GFP (231.luc.GFP) cells at low multiplicity of infection (MOI) to avoid 
integration of multiple kinases into a single cell. G418 selection of the kinase-overexpressing 
cells began at a concentration of 400 μg/mL and increased by 200 μg/mL every 3 days, up to 
a total concentration of 1 mg/mL. At this point, (14 days post-infection) RNA was isolated from 
some of the cells and analyzed by RT-PCR targeting a 250-bp sequence within the Neomycin 
resistance (NeoR) marker, which is contained in in the kinase library vector as a selection 
marker and conveys G418 resistance to eukaryotic cells. The results, seen in Figure 18, 
showed a band at the expected size of 250 bp.  
 
 
Figure 18. Neomycin resistance marker is present in MDA-MB-231 cells transfected with 
kinase ORF pools. Following retroviral transduction with kinase pools and G418 selection, RT-
PCR was performed using primers specific for a 250-bp portion of the G418 resistance marker. 
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The kinase pool-overexpressing 231.luc.GFP and corresponding control cells, which 
expressed tandem dimer Tomato, a bright RFP [tdTomato, (207)], were used for the brain 
metastasis growth screen. The cells were mixed at a 3:1 ratio (kinase pool:control), as the 
kinase pool population consisted of numerous (up to 24) subpopulations of cells overexpressing 
each kinases of the pool individually, and injected into 5 animals per pool via the left common 
carotid artery, see Figure 19 for details. Luciferase was detected in the mice 24 hours later, 
thus ensuring successful injections.  It was expected that if no kinases in a given pool imbued 
the 231.luc.GFP cells with a growth advantage, the mice would require euthanasia around day 
60 post-injection, based on previous observations on the growth characteristics of the MDA-
MB-231 cell line. Additionally, as the internal control cells were labeled with tdTomato instead 
of GFP, pools containing potential “hits” should lead to a much higher ratio of GFP:tdTomato 
signal by fluorescence imaging. 
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Figure 19. Schematic of in vivo kinome screen for drivers of brain metastatic growth. 
MDA-MB-231 parental cells (231p) stably expressing luciferase, GFP, and pools of up to 24 
kinases (231p.luciferase.GFP) were mixed with 231p cells expressing TdTomato and an empty 
pWZL-Neo-Myr-Flag-DEST vector (231p.TdTomato). Cells were mixed at a 3:1 ratio of kinase 
pool:vector and 2 x 106 cells were injected into nude mice. When animals displayed neurological 
symptoms and their heads were determine to be extremely luciferase-positive by IVIS, mice 
were sacrificed and brain lesions isolated using a dissecting microscope based on GFP-
positivity. Portions of the lesions were subjected to direct RNA extraction, while the remainder 
was dissociated and the cells cultured in vitro as passage 0. gDNA was extracted from the 
recovered cells and kinase vector sequences amplified by targeted PCR. This DNA was 
sequenced by MiSeq, yielding a quantitative readout of in vivo selection.  
 Indeed, most of the kinase pools led to dramatic phenotypes, with mouse survival 
reduced from 60 days to approximately 40 days, which is more reminiscent of the brain-selected 
line MDA-MB-231.Br (208) than the parental MDA-MB-231 cell line. Prior to euthanasia, the 
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mice were imaged by IVIS to determine luciferase signal (Figure 20). When the mouse brains 
were examined for fluorescence by dissecting microscope, it was evident that the GFP signal 
was predominant; any tdTomato signal observed in brains of mice sacrificed at early time points 
was of relatively minor contribution (Figure 21).  
 
Figure 20. IVIS images of pool 9 mice 45 days post-injection. Mice from pool 9 are shown 
for representative purposes. Mice are numbered 9-1 to 9-5 to reflect order in which they were 
euthanized. Mice 9-1, 9-2, and 9-3, which appear emaciated and hunched in this image, were 
sacrificed immediately following IVIS imaging, with 9-4 and 9-5 following 3 days later.  
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Figure 21. Mouse brains are strongly positive for GFP following injection with pool 9-
overexpressing cells. Mouse brains were removed and examined using a SteREO 
Discovery.V20 dissecting microscope (Zeiss). While some TdTomato signal was visible in the 
brains of injected mice (9-2 and 9-5), the lesions were predominantly GFP-positive. Fluorescent 
images shown are at 8x magnification. 
  
 After imaging brains for fluorescence, the tissue was finely minced; half was stored in 
RNAlater until the time of RNA extraction and half was used in an attempt to recover the in vivo-
selected tumor cells. The in vivo-derived cells recovered in this way were aliquoted when they 
reached 70-80% confluence and stored for later analysis (Figure 22, Table 4). 
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Figure 22. Brain metastasis cells recovered in vitro are GFP-positive. Fluorescence 
signals from tumor cells that were successfully recovered from in vivo lesions were assessed 
by an Olympus IX70 fluorescent microscope. Nearly all of the tumor cells were GFP-positive 
and TdTomato-negative. Images shown here are from mouse 9-1 (pool 9). Images were 
acquired using a 10x objective and DPController software (Olympus).  
 
Table 4. Summary of sample information for kinome screen experiments  
Pool 
number 
Animals in group Animals sacrificed before 
day 60 
Animals from which cells 
successfully recovered 
1 4 4 2 
2 5 5 4 
3 4 4 2 
4 5 4 4 
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5 5 5 4 
6 5 5 1 
7 5 5 5 
8 5 5 4 
9 5 5 5 
10 5 0 0 
11 4 4 3 
12 5 0 0 
13 5 5 3 
14 6 6 6 
15 5 5 3 
16 5 0 0 
17 5 4 2 
 
 
 To determine which kinases were responsible for the growth advantages observed in 
vivo, it was necessary to employ genetic sequencing techniques. Initially, RNA isolated directly 
from brains or those recovered cell lines successfully established from brain metastases was 
subjected to kinase vector-specific RT-PCR and analyzed by gel electrophoresis. The results 
showed that the banding patterns were indeed different in the in vivo-selected brain tissue and 
recovered brain metastatic cells compared to their corresponding pre-injection controls (Figure 
23).  
 
67 
 
Figure 23. PCR analysis provides evidence of selection occurring in vivo. DNA gel 
showing PCR (left) and RT-PCR (right) with kinase vector-specific primers. Banding pattern 
strikingly differs between in vitro, pre-injection cells (Pool 4) and tumor cells recovered from 
brain metastasis-bearing animals (4-1 through 4-4). 25ng of gDNA or 50ng of cDNA served as 
PCR templates. 
 
Following RT-PCR with Taq DNA polymerase, TOPO cloning was used to isolate 
individual kinase sequences. The pooled PCR products representing each in vivo sample were 
TOPO cloned, and 10 bacterial clones per each in vivo sample were grown in LB and 
miniprepped. The resulting DNA was sequenced, and this approach identified 8 kinase 
sequences isolated from in vivo samples from pools 1 to 5, included below in Table 5. 
 
Table 5. Kinase sequences detected by TOPO cloning of cDNA from recovered tumor 
cells from pools 1 to 5.  
NCBI Gene 
ID 
Official 
Symbol 
Gene Description RefSeq Accession 
Number 
1163 CKS1B CDC28 protein kinase regulatory 
subunit 1B 
NM_001826 
1111 CHEK1 CHK1 checkpoint homolog (S. 
pombe) 
NM_001274 
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7371 UCK2 uridine-cytidine kinase 2 NM_012474 
3932 LCK lymphocyte-specific protein tyrosine 
kinase 
NM_005356 
5127 PCTK1 PCTAIRE protein kinase 1, transcript 
variant 2 
NM_006201 
150274 RP3-
366L4.2 
J-type co-chaperone HSC20 NM_172002 
805 CALM2 calmodulin 2 (phosphorylase kinase, 
delta) 
NM_001743 
8877 SPHK1 sphingosine kinase 1 NM_021972 
 
  
Seeking a more quantitative and comprehensive identification of all those kinase 
sequences enriched in vivo, we set out to use NGS to analyze the brain metastatic cells 
recovered from the mice. Because of the stable retroviral integration of the kinase ORFs into 
the genome of the MDA-MB-231 prior to tumor cell injection, it was possible to analyze the 
gDNA of the tumor cells for kinase enrichment. gDNA was extracted from the pre-injection and 
recovered tumor cells, and quantitative PCR using kinase vector-specific primers performed on 
the gDNA (Figure 23, left). This DNA was barcoded and sequenced by MiSeq (Illumina). The 
raw sequence files were mapped to the human genome and the total read count of each 
barcode normalized by Dr. Jun Yao, a bioinformatician in the Department of Molecular and 
Cellular Oncology at UTMDACC. The reads of each kinase sequence in every brain metastasis-
derived sample were compared relative to their expression in the pre-injection kinase-
overexpressing cells (Figure 24), and the kinases were ranked according to average 
enrichment in vivo. Focusing only on those kinases enriched (relative expression >1) in multiple 
animals resulted in a list of 31 sequences (Table 6). 
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Figure 24. Coverage plots reveal relative sequence enrichment following in vivo 
selection. Comparison of kinase sequence read counts prior to and following in vivo selection 
demonstrates appreciable loss of most sequences in vivo. The lone exception, indicated with a 
blue arrow, is MAPK12, which had its read count rise from just over 2 million to 11 million. 
Coverage plots were generated with MiSeq Reporter.  
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Table 6. Kinase sequences enriched in vivo as determined by NGS.  
NCBI 
Gene ID 
Official 
Symbol 
Gene Description RefSeq Accession 
Number 
79934 ADCK4 aarF domain containing kinase 4 NM_024876 
269 AMHR2 anti-Mullerian hormone receptor, type II NM_020547 
695 BTK Bruton agammaglobulinemia tyrosine kinase NM_000061 
805 CALM2 calmodulin 2 (phosphorylase kinase, delta) NM_001743 
808 CALM3 calmodulin 3 (phosphorylase kinase, delta) NM_005184 
814 CAMK4 calcium/calmodulin dependent protein kinase 
IV 
NM_001744 
1020  CDK5  cyclin-dependent kinase 5  NM_004935 
8851 CDK5R1 cyclin-dependent kinase 5, regulatory subunit 
1 (p35) 
NM_003885 
1198 CLK3 CDC-like kinase 3 NM_001292 
26007 DAK dihydroxyacetone kinase 2 homolog NM_015533 
2444 FRK fyn-related kinase NM_002031 
3099 HK2 hexokinase 2 NM_000189 
3985 LIMK2 LIM domain kinase 2 NM_005569 
5609 MAP2K7 mitogen-activated protein kinase kinase 7 NM_145185 
6300 MAPK12 mitogen-activated protein kinase 12 NM_002969 
5598 MAPK7 mitogen-activated protein kinase 7, transcript 
variant 2 
NM_002749 
57787 MARK4 MAP/microtubule affinity-regulating kinase 4 NM_031417 
10298 PAK4 p21(CDKN1A)-activated kinase 4 NM_001014831 
5106 PCK2 phosphoenolpyruvate carboxykinase 2 
(mitochondrial) 
NM_004563 
5127 PCTK1 PCTAIRE protein kinase 1, transcript variant 2 NM_006201 
5211 PFKL phosphofructokinase, liver NM_001002021 
5213 PFKM phosphofructokinase, muscle NM_000289 
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10654 PMVK phosphomevalonate kinase NM_006556 
5567 PRKACB protein kinase, cAMP-dependent, catalytic, 
beta 
NM_002731 
5568 PRKACG protein kinase, cAMP-dependent, catalytic, 
gamma 
NM_002732 
5580 PRKCD protein kinase C, delta NM_006254 
5584 PRKCI protein kinase C, iota NM_002740 
6794 STK11 serine/threonine kinase 11 NM_000455 
83983 TSSK6 testis-specific serine kinase 6 NM_032037 
7371 UCK2 uridine-cytidine kinase 2 NM_012474 
51530 ZC3HC1 zinc finger, C3HC-type containing 1 NM_016478 
 
 Generating such an extensive list of potential novel drivers of brain metastatic growth 
was promising; however, as the kinome screen was performed in a pooled format, the possibility 
existed that some of the would-be hits were mere artifacts of the screening process, passenger 
genes being buoyed by their neighbors. Therefore, all the potential hits require functional 
validation before being truly implicated in brain metastasis. In order to do so, the ORFs 
representing the potential “hit” kinases were individually used to generate stable MDA-MB-231 
transfectants. As it would have been time- and cost-prohibitive to interrogate all 31 ORFs in 
mice, another filter for hit prioritization proved necessary. Tumor cell growth in hard agar (0.9%) 
has been previously established to be indicative of brain metastasis-initiating potential (209), a 
secondary functional screen was performed on single ORF-overexpressing cell lines. The 
assay indeed demonstrated differences among the potential hits in their ability to form colonies 
in hard agar, further informing “hit” ranking (Figure 25, Table 7). 
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Figure 25. In vitro hard agar growth assay of single kinase-overexpressing MDA-MB-231 
cells shows that overexpression of most kinases enhances colony formation. Colonies 
>75 μm following 60 days of culture were counted. One-way ANOVA showed significant 
difference between groups, F(22,46)=15.56, p<0.0001. Fisher’s LSD multiple comparisons test 
showed that the top 10 cell lines had a statistically significant colony-forming advantage over 
the vector group, indicated with * on the graph. Experiments were performed in triplicate. Error 
bars indicate SEM of colony number per well. 
 
Because the kinome screen was based on the principle of generating artificial 
heterogeneity prior to testing for in vivo selection, it was necessary to demonstrate that the 
newly identified hits are actually expressed in human brain metastases and did not exist 
exclusively in the artificial setting of this screen. Through a collaboration with the a group from 
the University of Queensland (Australia), we examined the expression of all potential hits by 
RNA-seq of a collection of 32 human brain metastasis specimens, including 8 cases of breast 
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cancer (205). Analysis showed again showed a wide range of expression, with CALM2 and 
HK2 expressed in the top 5% of all expressed genes (Figure 26, Table 7). 
 
Figure 26. Expression of putative kinase hits in human brain metastasis according to 
RNA-seq. Genes are ordered according to average expression (normalized to transcripts per 
million reads, nCPM) in all samples. Solid gray line distinguishes those genes expressed as 
upper outliers, calculated as [Q3+(1.5 x IQR)]. Dashed gray line indicates those genes 
considered as “expressed,” as their transcript expression level was greater than 1 transcript per 
million. Error bars indicate SEM of nCPM. 
 
 The expression data in brain metastasis was then combined with the hard agar colony-
forming ability to rank the potential hit kinases in order of likelihood of their contribution to 
accelerated brain metastatic growth. The top-ranking potential hit thus identified was PCTK1 
(Table 7). 
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Table 7. PCTK1 is the top candidate kinase based on hard agar colony-forming ability 
and expression in human breast cancer brain metastases.  
Gene Hard agar colony 
formation rank 
Human brain metastasis 
expression rank 
Rank-sum 
PCTK1 5 5 10 
STK11 1 13 14 
CALM3 14 3 17 
CLK3 3 14 17 
HK2 15 2 17 
PRKACB 11 6 17 
LIMK2 10 8 18 
PRKCI 11 7 18 
PFKM 8 11 19 
CALM2 19 1 20 
DAK 2 19 21 
PFKL 17 4 21 
FRK 11 10 21 
UCK2 16 9 25 
PMVK 11 15 26 
CDK5R1 4 23 27 
MAP2K7 11 16 27 
PRKCD 11 18 29 
MAPK7 9 21 30 
MARK4 20 12 32 
ADCK4 13 20 33 
ZC3HCI 12 22 34 
AMHR2 7 28 35 
PRKACG 6 29 35 
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CAMK4 11 26 37 
PCK2 21 17 38 
TSSK6 11 27 38 
BTK 11 30 41 
PAK4 11 31 42 
MAPK12 18 25 43 
CDK5 22 24 46 
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Chapter 4: Investigation and validation of PCTK1 as a driver of brain metastatic growth 
 PCTK1, also known as cyclin-dependent kinase 16 (CDK16), is a serine/threonine 
kinase originally named PCTAIRE-1 after its discovery in 1992 (210). It exists in 3 isoforms, 
with isoform 1 encoding a protein of 55.7 kilodaltons (kDa) and isoforms 2 (63.4 kDa) and 3 
(56.4 kDa) possessing extended N-terminal domains. It is classified as an atypical cyclin-
dependent kinase (cdc2/CDC28-related protein kinase gene family) family member, as its 
cyclin-binding domain contains a serine to cysteine substitution (i.e., PCTAIRE instead of 
PSTAIRE) (210). This non-traditional cyclin-binding domain leads to binding of cyclin Y (CCNY) 
(211). A PCTK1 knockout mouse model revealed that PCTK1 is indispensable for 
spermatogenesis; homozygous knockout male mice are infertile, while females produce viable 
offspring (211). No other phenotypes of the knockout model were noted (211). However, 
commensurate with its mRNA expression in the brain, PCTK1 has also been shown to regulate 
neuronal differentiation and outgrowth (212). Intriguingly, this kinase has also been identified 
as a substrate of CDK5, another kinase identified in the previous in vivo kinome screen (213). 
Phosphorylation of PCTK1 by activated CDK5 is required for its activity in dendrite development 
(214).  
 In spite of the gains made in better understanding the physiological roles of PCTK1, a 
great deal of its characterization remains elusive. First and foremost, as a kinase, PCTK1 is 
thought to primarily function through phosphorylation of downstream targets. Indeed, it 
possesses an activation loop and has been shown to phosphorylate N-ethylmaleimide-sensitive 
fusion protein (NSF) (215), KAP0 (216), and cyclin Y (217). However, elegantly designed 
studies attempting to characterize a consensus substrate motif for PCTK1 have failed to agree 
with each other (216, 218), although they did both conclude that the PCTK1 substrate motif 
does not coincide with that of typical CDK family motifs. In addition to the lack of clarity of 
PCTK1’s targets, its upstream regulators remain a topic of debate, as the role of cyclin Y as the 
sole activator of PCTK1 has been questioned, with both cyclin Y-like 1 (CCNYL1) (219) and 
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CDK5 (212) suggested as alternative regulators. Therefore, unlike classic proliferation-related 
cyclins, it may be that the activity of PCTK1 is totally independent of cyclin binding. 
 PCTK1 has only recently been implicated in cancer, and its biological roles in this 
disease setting remain largely unresolved. It has been demonstrated in vitro that PCTK1 
knockdown sensitizes prostate and breast cancer cells to the TNF-related apoptosis-inducing 
ligand (TRAIL) extrinsic cell death pathway (220). Additionally, PCTK1 has been shown in 
prostate cancer cells to phosphorylate the tumor suppressor p27 (also known as Kip1, cyclin-
dependent kinase inhibitor 1B), resulting in its degradation and cell cycle progression (221). In 
an in vitro screen, it was shown that siRNA-mediated knockdown of PCTK1 slowed the growth 
of a MYC-amplified medulloblastoma cell line, suggesting PCTK1’s involvement in the 
mammalian target of rapamycin (mTOR) pathway. Lastly, PCTK1 has been shown to be 
overexpressed at the mRNA and protein levels in serous epithelial ovarian carcinoma (EOC) 
tissues compared to matched normal tissues, although the authors suggest that this is a 
negative feedback mechanism to promote the differentiation of tumor cells and inhibit 
proliferation. Notably, the involvement of PCTK1 in metastasis has thus far been unexplored. 
PCTK1 was the top candidate kinase based upon its expression in clinical brain 
metastasis as well its ability to enhance colony formation in hard agar, but because the kinome 
screen was performed in a pooled format, it was necessary to functionally validate PCTK1 in a 
single kinase-overexpression context. Therefore, the PCTK1-overexpressing MDA-MB-
231.luc.GFP (231.PCTK1) and its corresponding control line (231.vector) generated for the 
hard agar screening experiments were validated for PCTK1 overexpression at the mRNA and 
protein levels (Figure 27) and were injected into the carotid artery of mice (100,000 cells per 
mouse). The cell number was halved in this experiment compared to the kinome screen in order 
to provide a larger window of observation. Following intracarotid injection, the mice were 
monitored weekly by IVIS luciferase imaging and sacrificed when they reached morbidity. 
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Figure 27. PCTK1 is overexpressed at RNA and protein level in 231.PCTK1 cells.  Left: 
qRT-PCR with TaqMan primers shows that PCTK1 mRNA expression is enhanced more than 
sixfold compared to controls. qRT-PCR of 18S mRNA was used for normalization. The p-value 
was <0.0001 according to unpaired t-test. Right: Western blot for PCTK1 protein expression. 
β-actin was used as a loading control. 
 
PCTK1 overexpression led to enhanced brain metastatic growth relative to the vector 
control cells to the extent that luciferase images of the mouse brains began to become saturated 
by day 32 post-injection (Figure 28). Additionally, PCTK1-overexpressing cells significantly 
reduced mouse survival relative to the control group, demonstrating that PCTK1 indeed can 
accelerate brain metastasis growth even outside the pooled format of the kinome screen 
(Figure 29). The brain metastases formed by 231.PCTK1 were invasive from the leptomeninges 
into the parenchyma, and formed large ventricular masses, while 231.vector mostly formed 
smaller tumors in the ventricles (Figure 30). 
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Figure 28. PCTK1 overexpression enhances brain metastasis growth in vivo. IVIS imaging 
was performed using an IVIS-200 (Xenogen) to assess the growth of brain metastases in vivo. 
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MDA-MB-231.luciferase cells expressing vector (231.vector) or PCTK1 (231.PCTK1) were 
injected into the carotid artery of nude mice to form experimental brain metastasis (each group: 
n = 10). Metastatic growth in the brain was measured beginning 1 day post-injection by 
luciferase activity. Top: IVIS images from 5 representative mice per group are shown. The scale 
bar to the right of the images indicates signal intensity, a surrogate marker of brain metastasis 
burden. The signal from mice injected with 231.PCTK1 started to become saturated by day 32 
post-injection. Bottom: quantification of IVIS luciferase signal. The y-axis shows the amount of 
luminescence captured from a defined region of interest (ROI), which was an oval-shaped 
region of standardized size around each animal’s head. T-tests were performed at each time 
point and the Holm-Sidak method was used to correct for multiple comparisons. 
 
 
 
Figure 29. PCTK1 overexpression in MDA-MB-231 significantly shortens survival in 
experimental brain metastasis model. Mice injected intracarotidly with 231.PCTK1 or 
corresponding vector cells were compared for their brain metastasis-specific survival. PCTK1 
overexpression shortened survival from a median time of 128 days to 60 days. Survival curves 
were significantly different (p=0.0004) according to Mantel-Cox log-rank test. 
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Figure 30. PCTK1 overexpression enhances brain metastasis growth in ventricles and 
invasion into the parenchyma. (A) and (B): Hematoxylin and eosin (H&E) staining of 
231.vector brain metastases. 231.vector cells formed lesions in the ventricles (A) and small 
lesions in the parenchyma (B). (C) and (D) H&E staining of 231.PCTK1 brain metastases. (C) 
shows tumor cells growing throughout the parenchyma,  while (D) shows 231.PCTK1 cells filling 
the ventricle. All images acquired at 10x magnification; scale bars represent 200 µm. 
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After the observation of PCTK1’s enhancement of brain metastasis, and given the limited 
functional knowledge about PCTK1, a natural question was whether the PCTK1-driven tumor 
growth was metastasis-specific or a shared feature of primary tumors and metastases. 
Therefore, luciferase-labeled 231.vector or 231.PCTK1 were injected into the mammary glands 
of nude mice to form mammary fat pad tumors (each group: n = 12 [6 mice with bilateral 
tumors]). PCTK1 overexpression did not lead to enhanced primary tumor growth in this model, 
suggesting that its pro-tumoral functions are metastasis-specific (Figure 31).    
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Fig 31. PCTK1 overexpression does not enhance primary mammary tumor growth. 
231.PCTK1 and 231.vector were injected into the #3 mammary glands of nude mice. Injection 
efficiency was measured on day 1 by IVIS. Once tumors became palpable, they were regularly 
measured by calipers. Tumor volume estimates, calculated by the formula (L x W2)/2 and 
normalized to IVIS signal on day 1, are shown in A. Tumor mass as determined at the 
experimental endpoint is shown in B. Unpaired t-tests, using the Holm-Sidak method to correct 
for multiple comparisons, revealed no significant growth differences. 
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 To characterize the cellular mechanism by which PCTK1 enhances brain metastatic 
growth of MDA-MB-231 cells, basic cellular phenotypic characteristics, including proliferation, 
invasion, and migration were assessed in vitro under normal culture conditions, i.e., DMEM/F12 
media supplemented with 10% FBS. The results, as shown below in Figure 32, indicated that 
PCTK1’s dramatic pro-metastasis phenotype was not recapitulated in vitro. 
 
 
Figure 32. PCTK1 overexpression does not promote proliferation, migration, or invasion 
in vitro. (A) MTT assays demonstrated a statistically significant difference at the 2 day time 
point, but no dramatic biological difference was observed. (B) Transwell migration assay of 
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231.vector and 231.PCTK1 at 18 hours showed no significant difference. (C) Invasion through 
Matrigel at 24 hours was inhibited by PCTK1 overexpression. Unpaired t-tests were used to 
compare groups in each experiment and the results are indicated as * on graphs. In A, 
correction for multiple comparisons was performed. 
 
Based on the characterization of PCTK1 as a non-canonical cyclin-dependent kinase, 
the fact that it provided no major growth advantage in vitro was unsurprising. At the same time, 
the strikingly rapid growth of PCTK1-overexpressing brain metastatic cells in vivo demanded 
explanation. As mentioned in Section 1.3.2, the brain represents a vastly distinct habitat 
compared to the primary tumor site, especially with regards to resource availability. Therefore, 
to examine whether growth advantage conferred by PCTK1 in brain metastasis may be related 
to the unique metabolic microenvironment of the brain, correlations of PCTK1 gene expression 
with the expression of members of the glutamine metabolism pathway were analyzed (Figure 
33, A - E). Strikingly, in primary breast cancer as well as glioblastoma, PCTK1 showed strong 
relationships with expression of glutamine metabolizing genes, including asparagine 
synthetase (ASNS). These relationships were even stronger in low-grade glioma, where they 
extended to both forms of the classical glutamine catabolism gene glutaminase, glutaminase 1 
and 2 (GLS and GLS2). 
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Figure 33. PCTK1 shows strong correlations with glutamine metabolism genes in TCGA 
data.  The gene expression values of PCTK1 (CDK16) and members of the glutamine metabolic 
process (Gene Ontology: 0006541) family were compared within TCGA datasets of ER-positive 
breast cancer (A), HER2-positive breast cancer (B), TNBC (C), glioblastoma (GBM) (D), and 
low-grade glioma (LGG) (E). Pairwise Pearson correlation coefficient values between genes 
were generated and reordered using a clustering algorithm based on the similarity between 
genes. Genes with highly positive correlative values appear in red, those with highly negative 
values in blue, and those lacking correlation in white. PCTK1 is highlighted in each graph. Data 
matrices were generated by Dr. Patrick Zhang. 
 .  
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In consideration of this correlative relationship with glutamine metabolism, the effect of PCTK1 
was functionally assayed in vitro in low nutrient conditions. For this purpose, Basal Medium 
Eagle (BME), which was developed by Harry Eagle in the 1950s for growing HeLa cells (222, 
223), was selected. Basal Medium Eagle contains approximately one-third the glucose and 
one-fourth the amino acid content of DMEM/F12, which is more widely used in cell culture 
because its nutrient surplus supports a higher growth rate. Importantly, when 231.PCTK1 and 
231.vector were previously compared for their proliferative abilities in vitro, DMEM/F12 media 
was used. When the assay was repeated using BME supplemented with 500 μM glutamine 
(representative of physiological level in the brain), PCTK1 overexpression imbued the cells with 
a striking growth advantage (Figure 34). This result provided an indication that PCTK1 may 
allow cells to better metabolize glutamine when faced with low-nutrient conditions, such as that 
of the brain.  
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Figure 34. PCTK1-overexpressing cells have a survival advantage in low-nutrient 
conditions when glutamine is available 231.PCTK1 cells or 231.vector cells were plated with 
or without 500 μM of glutamine. After one week, cell growth was assessed by an Olympus IX70 
microscope. Representative images at 10x magnification are shown. 
 
  
 Because the exchange of glutamine and glutamate occurs in the brain in a cyclical 
fashion, it was unclear whether the PCTK1-overexpressing cells were using the glutamine from 
the media directly, or perhaps were driven to proliferation by activation of glutamate receptors. 
Therefore, the relative abilities of PCTK1-overexpressing and associated vector control MDA-
MB-231 cells to proliferate using similar concentrations of either glutamate or glutamine were 
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assayed in low-nutrient BME. While vector-expressing cells were unable to grow with either 
glutamate or glutamine supplementation, the PCTK1-overexpressing cells demonstrated a 
strong growth advantage evident at glutamine concentrations ranging from 400 μM to 2mM 
(Figure 35A). However, even the PCTK1-overexpressing cells were unable to grow with 
comparable levels of glutamate supplementation (Figure 35B). These results suggested that 
PCTK1-overexpressing tumor cells indeed behave similarly to neurons under limiting nutrient 
conditions, with an ability to use glutamine but not glutamate for survival and/or proliferation.  
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Figure 35. PCTK1-overexpressing cells have proliferative advantage in limited-nutrient 
media supplemented with glutamine, but not glutamate. MDA-MB-231 cells with or without 
PCTK1 expression were cultured in BME with the given quantities of glutamine (A) or glutamate 
(B) for 4 days. MTT assays were performed, and the results are shown in terms of MTT signal 
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at 570 nm minus the background at 650 nm (OD 570-650). T-tests were performed at each 
concentration, with the Holm-Sidak method used to correct for multiple comparisons. 
 
 While the previous results indicated that 231.PCTK1 cells were using glutamine in order 
to maintain their survival and proliferation in conditions of limited nutrients, it remained unknown 
whether the cells were indeed taking up more glutamine and either using it for energy or 
incorporation into the biomass of new cells, or simply processing the glutamine a byproduct of 
a homeostatic glutamine-glutamate cycle. In order to directly test these possibilities, the media 
of PCTK1-overexpressing and vector MDA-MB-231 cells was analyzed by mass spectrometry. 
In order to calculate the relative rates of substrate utilization, media was collected at the 
specified timepoints (0, 1.5, 3, and 6 hours) and the relative peaks of glutamine and glutamate 
compared. Because of the sensitivity of the experiment to environmental conditions, wells 
included as replicates were randomly selected from different regions of the cell culture plates 
(See schematic, Figure 36).  
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Figure 36. Schematic of MS experiment to determine relative glutamine and glutamate 
utilization rates in PCTK1-overexpressing cells. (A) Cells were cultured in 12-well plates in 
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300 μL BME with exactly 500 μM glutamine at the start of the assay. Media was collected from 
wells sampled from around the plate at time points indicated within circles (times are in hours) 
and centrifuged at 2000 x g for 5 minutes to remove cellular debris. The media from earlier time 
points was stored at -80°C until completion of the assay, at which time all samples were 
analyzed for glutamine and glutamate content by YSI Bioanalyzer. (B) Results indicated that 
the rate of glutamine intake rose in 231.PCTK1 cells, while at the same time the glutamate 
output rate actually decreased. 
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Figure 37. PCTK1 overexpression significantly enhances glutamine metabolism. (A)  Left, 
glutamine depletion rates in the media of 231.vector and 231.PCTK1 were compared by MS. 
There was a trend towards increasing glutamine consumption with PCTK1 overexpression. 
Right, similar comparisons were made for glutamate release into the media of cultured cells. 
There was a significant decrease in glutamate release from PCTK1-overexpressing cells. (B) 
The rate of glutamate production was normalized to the rate of glutamine consumption. PCTK1 
overexpression led to a deficit in glutamate production per glutamine consumed of nearly 50%. 
Unpaired t-tests were used to compare groups in each experiment and the results are indicated 
as * on graphs. 
 
These results demonstrated several important points. First, the rates of glutamine 
consumption from and glutamate release into the media remained in the linear range over the 
time frame assayed, for simplicity the 0 hour and 6 hour time points were compared. Compared 
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to 231.vector cells, the PCTK1-overexpressing cells increased their uptake of glutamine from 
the media by 35% (Figure 37A, left). At the same time, there was a reduction in glutamate 
release from the PCTK1-overexpressing cells, with the relative rate falling by more than 25% 
(Figure 37A, right). Together, these rates meant that for every 1 unit of glutamine going into the 
cells, PCTK1-expressing cells were producing 48% less glutamate (Figure 37B). This deficit 
between expected glutamate release and actual glutamate release implies that the glutamine 
is staying in the cell for either energy or biomass generation.  
Finally, as all of the prior experiments had been based on a gain-of-function system, 
loss-of-function studies were performed in order to test whether PCTK1 was necessary for brain 
metastasis in vivo.  To that end, PCTK1 stable knockdown cell lines were generated from the 
HCC1954Br cell line (1954Br), a highly aggressive HER2-overexpressing breast cancer cell 
line that also possesses a high endogenous level of PCTK1. PCTK1 knockdown efficiency at 
the mRNA and protein levels for the 2 best clones are shown below in Figure 38. HCC1954Br 
shControl and HCC1954Br shPCTK1-3 were then injected into the carotid artery of nude mice. 
Following intracarotid injection, the mice were monitored for development of brain metastasis 
symptoms and sacrificed when they reached morbidity. 
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Figure 38. PCTK1 is efficiently knocked down in the HCC1954Br cell line. Left: qRT-PCR 
with TaqMan primers shows that PCTK1 mRNA expression is decreased 90% in both 
knockdown lines compared to control line. qRT-PCR of 18S mRNA was used for normalization. 
The p-value was <0.0001 according to one-way ANOVA followed by Dunnett’s multiple 
comparisons test. Right: Western blot for PCTK1 protein expression showing efficient 
knockdown with both shRNA clones. β-actin was used as a loading control. 
  
99 
 
 
Figure 39. PCTK1 knockdown in HCC1954Br significantly extends survival of brain 
metastasis-bearing mice. Mice injected intracarotidly with 1954Br shControl or shPCTK1 
were compared for their brain metastasis-specific survival. PCTK1 knockdown lengthened 
survival from a median time of 57.5 days to 91 days. Survival curves were significantly different 
(p=0.046) according to Mantel-Cox log-rank test. 
100 
 
 
Figure 40. PCTK1 knockdown does not affect morphology of brain metastasis in 
HCC1954Br model. Representative H&E staining of brain metastasis formed by ICA injection 
of (A) HCC1954Br shControl cells on day 49 post-injection or (B) HCC1954Br shPCTK1-3  cells 
on day 91 post-injection. No major morphological differences were apparent between groups, 
with both exhibiting parenchymal growth, large volume, and abundant vasculature. All images 
acquired at 10x magnification; scale bars represent 200 µm. 
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 Knockdown of PCTK1 in the 1954Br cell line significantly enhanced mouse survival 
relative to controls in an experimental brain metastasis model, with median survival times rising 
from 57.5 days in the control group to 91 days in the knockdown group (Figure 39). However, 
as most mice injected with PCTK1 knockdown clones eventually succumbed to brain 
metastases with morphology resembling the control tumors (Figure 40), knockdown of PCTK1 
unsurprisingly did not seem to be a curative approach. To investigate whether the expression 
of PCTK1 recovered in vivo, either through adaptation or selection of clones with inefficient 
knockdown, the protein level of PCTK1 was assessed by IHC. Indeed, IHC analysis showed 
that PCTK1 expression can recover in vivo (Figure 41), indicating either that the incomplete 
efficiency of shRNA in eliminating protein expression or the selection of especially poor 
knockdown clones in vivo.   
  
102 
 
 
 
Figure 41. PCTK1 protein expression can recover in vivo in HCC1954Br brain 
metastasis with PCTK1 shRNA knockdown. Representative PCTK1 IHC staining of brain 
metastasis formed by ICA injection of (A & B) HCC1954Br shControl cells or (C & D) 
HCC1954Br shPCTK1-3 cells. Both the control and PCTK1 knockdown brain lesions show 
heterogeneous PCTK1 expression, with areas of almost uniform positivity and negativity both 
apparent. All images acquired at 20x magnification; scale bars represent 100 µm.  
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Chapter 5: Discussion, Conclusions, and Future Directions 
Discussion 
Breast cancer is one of the most common and deadly cancers among women in the 
United States, as almost 250,000 new cases will be diagnosed in 2016, and an expected 40,500 
deaths due to breast cancer. In the past 30 years, the increase in screening and targeted 
therapies for breast cancer has seen the death rate fall by almost one-third from its peak in 
1989. However, this improvement is almost entirely due to effects in detecting early-stage 
disease earlier; once cancer has metastasized, the prognosis remains bleak, as patients 
diagnosed with stage IV disease (distant metastasis) have only a 22% 5-year survival. 
 The metastasis of cancer to secondary sites is not a random process, as cancers from 
certain organ sites have their own preferential sites for metastasis. The ‘seed and soil’ principle 
holds that successful metastasis only occurs when the right cancer cell seed interacts with the 
appropriate supportive secondary organ soil. First espoused by English surgeon Stephen Paget 
in 1889 and validated by Isaiah Fidler in the 20th century, the seed and soil theory has stood 
the test of time. For breast cancer seeds, the common metastatic soils are bone, liver, lungs, 
and brain. While any metastatic breast cancer diagnosis is generally fatal, brain metastasis 
carries a brutal prognosis, with median survival of less than one year.  
 The especially poor prognosis for brain metastasis is not limited to the context of breast 
cancer. Other cancers that frequently metastasize to the brain include lung, breast, melanoma, 
and colorectal; once they are in the brain, all are incurable. While one explanation is the fact 
that brain metastases usually develop in heavily pre-treated patients, so do metastases to other 
organ sites that can demonstrate responses to therapy; brain metastases’ therapeutic 
resistance is likely due to the unique biology of the brain. In either case, the clinical options for 
brain metastasis are only palliative; this and the fact that it is not even fully resolved as to why 
secondary cancers of the brain do not respond to therapy represent true failures by the clinical 
and biomedical research communities. 
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 In cancer settings other than brain metastasis, molecular targeted therapies against 
cancer drivers, frequently kinases, have demonstrated widespread clinical efficacy. 
Additionally, as kinases occupy the key nodes of cancer cell signaling pathways, they are 
involved in many of the cellular functions and dysfunctions that represent the hallmarks of 
cancer. In vitro, kinase overexpression screens have identified previously unknown oncogenes. 
Finally, while genomic and transcriptomic studies comparing brain metastases to either primary 
cancers or non-brain metastasis have identified a number of brain-specific genes that play roles 
in brain metastasis, these studies are restricted to those genes whose mRNA expression 
remains significantly altered following the formation of brain metastasis. As the process of 
metastasis involves many diverse and demanding steps, genes that provide an advantage at 
one step may be antagonistically pleiotropic, causing their loss of expression at later stages. 
Therefore, we set out to identify novel kinase drivers of brain metastasis through a 
functional genomic screen in vivo, hypothesizing that kinases previously unknown to play roles 
in brain metastasis may actually imbue cancer cells with growth advantages in the brain. By 
using the intracarotid injection method of inducing experimental brain metastasis, the cells are 
delivered into the capillary bed of the brain, allowing for the observation of brain metastasis, 
which is incredibly rare in other models. This also has the effect of focusing the interrogation of 
the metastatic cascade to the final few steps: extravasation, colonization, and growth at the 
secondary site. Because the dissemination of cancer cells throughout the body usually occurs 
early, understanding these steps is key to the future of therapy for metastasis. The MDA-MB-
231 parental cell line was selected as the cancer cell background for the screen, because as 
the line is able to induce brain metastasis with high efficiency but relatively long latency, it offers 
a window for observing enhanced brain metastasis. One noteworthy drawback of this approach 
is that the use of cross-species xenografts as models of cancer and metastasis involves the 
growth of human cells in immunocompromised mouse hosts. In this study, nude mice were 
used as the hosts for metastasis experiments, as the “nude” mutation in FOXN1 that causes 
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their hairlessness also leads to the absence of a thymus and deficient T cell development, 
thereby allowing the growth of foreign cells that would otherwise be rejected by 
immunocompetent animals (224). While the use of immunocompromised mice enables the 
interrogation of cancer cell growth dynamics in organ-specific nutrient environments much 
closer to approximating human disease than does in vitro cell culture, the artificial nature of 
such a system should not be understated. As cancer immunotherapy continues to lead to 
dramatic clinical results in cancer therapy, the immune system is obviously a key regulator in 
protecting against cancer and metastasis outgrowth and colonization, and the use of 
immunocompromised animal models downplays this factor. Studies on the importance of the 
immune system in curtailing brain colonization and growth by metastatic tumor cells could make 
use of mouse cancer cell lines such as 4T1 in a syngeneic mouse background of BALB/c, 
although the use of non-human cancer cell lines also raises questions of real disease relevance. 
As statistician George Box said, “all models are wrong; some are useful.” With this in mind, 
here I chose to focus on an experimental model system with certain limitations (experimental 
metastasis model in immunocompromised mice), in hopes of identifying some novel truths that 
could be validated in other systems later. While a pure brain metastasis gain-of-function screen 
in a spontaneous mammary fat pad tumor model or non-brain tropic cell line using a syngeneic 
immunocompetent mouse strain would have been much less likely to generate successful 
phenotypes, and was not pursued here, this approach could be taken by audacious researchers 
in the future. 
The screen resulted in clear demonstration that kinase overexpression enhanced brain 
metastasis growth, as 14 of the 17 pools decreased mouse survival shorter than the 60 days 
seen in the parental cell line. Following this positive in vivo data, though, recovery of the identity 
of the kinases involved was non-trivial. During the screen, as the mice were euthanized, their 
brains were harvested; half of the metastases-bearing tissue (as estimated by GFP signal under 
dissecting microscope) was used for direct RNA extraction and half was dissociated and cells 
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were recovered from the dissociated tissue in vitro. The RNA from the brain metastasis lesions 
was isolated and used to produce cDNA, which was then subjected to RT-PCR with vector-
specific primers. The resulting PCR products were then TOPO cloned and subjected to 
sequencing 
While this methodology did yield some potentially interesting data, it was clear that there 
were limitations. First, it did not provide a quantitative measure of the kinases being detected. 
Simple identification of a kinase sequence from in vivo tissue did not necessarily indicate that 
a given kinase was enriched in vivo, merely that it was not completely lost from the population. 
More importantly, while 5 sequences were identified from pool 2, only 1 was recovered from 
pool 1 and 2 from pool 3, with none coming from pool 4 or 5 in spite of their increased brain 
metastatic growth and the fact that multiple bands were visible in gels analyzing their RT-PCR 
products. This was partially due to the fact that the kinase library contained 353 ORFs, but 
came with 409 wells of bacterial glycerol stock. The extra 56 wells, which were distributed 
throughout the plates of the library, contained the kinase ORF vector plasmid loaded with a 
“filler” DNA sequence, in many cases a segment of TGFBR2. Since these filler sequences were 
very short, they preferentially amplified during the PCR process and overwhelmed the true ORF 
sequences during the TOPO cloning process, thereby obfuscating kinase identity. 
When it became clear that the TOPO cloning method was not optimal for identifying the 
kinases positively selected in vivo, the method for kinase identification was modified, instead 
using NGS of genetic materials isolated from recovered tumor cells compared to the pre-
injection cells. Prior to performing NGS, a comparison was made between the detection 
capabilities of kinase library gDNA by PCR and mRNA by RT-PCR; gDNA allowed for 
amplification of more sequences and was thus chosen for further NGS analysis. The MiSeq 
NGS method allowed for the quantitative measurement of kinase enrichment in vivo, and was 
only limited by the fact that successful cell recovery was only achieved for 48/66 in vivo 
samples. As the kinase library was expressed in a retroviral vector and stably selected prior to 
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injection, it was possible to query the genomic DNA for kinase ORF presence without 
dependence on a cDNA synthesis step. This NGS analysis revealed 31 kinases that were 
enriched in multiple animals in vivo, many of which were previously unlinked to brain 
metastasis. Of note, 2 of the ORFs (CALM2 and PCTK1) identified by the TOPO cloning method 
appeared in the list of kinases enriched in vivo. However, the other 6 ORFs identified by that 
method were not enriched, demonstrating the superiority of the NGS method in determining 
quantitative measures of enrichment. 
The overexpression of kinases in a pooled format offered the ability to survey a wider 
range of kinase species simultaneously. In a small pilot study in a second cell line, we attempted 
the screen with kinase pools of doubled size, representing approximately 40 kinases per pool. 
These pools appeared to be too large, as there was no minimal consistency mouse-to-mouse 
in terms of which kinases were enriched. However, the recovery and sequencing of this pilot 
study was only performed using the TOPO cloning/Sanger sequencing method. By using the 
MiSeq system for NGS, performing a similar screen with larger pool sizes should be possible. 
Results could also be made more robust by including more animals, or by direct isolation and 
sequencing of genomic DNA from tumor cells isolated from brain by either FACS or magnetic 
bead-based isolation. 
Importantly, the kinome screen as performed did reveal several kinases potentially 
playing important roles in brain metastasis. Notably, HK2, which controls the first step of 
glycolysis and has previously been implicated in brain metastasis (191), was one of the top hits 
identified by this screen. Intriguingly, 3 other kinases enriched in vivo in multiple animals, 
phosphofructokinase-liver (PFKL), phosphofructokinase-muscle (PFKM), and 
phosphoenolpyruvate carboxykinase 2 (PCK2), are all associated with the utilization of glucose. 
As brain metastasis has been shown to be reliant upon glucose for both the glycolytic and 
pentose phosphate pathways (192), this serves as an indicator that the screen revealed 
potentially relevant hits. Indeed, the study of cancer has focused almost exclusively on the use 
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of glucose as an energy substrate. To wit, Otto Warburg’s observations on the preference of 
cancer cells to obtain energy by anaerobic glycolysis serve as the basis for the Warburg 
hypothesis (225) and 18-FDG PET imaging relies on the preferential glucose metabolism by 
cancer cells as a means of differentiating them from healthy tissue (226). Intriguingly, though, 
while HK2, PFKL, and PFKM all are involved in glucose metabolism via glycolysis, suggestive 
of a Warburg effect, PCK2 plays the opposite role in glucose metabolism by its regulation of 
gluconeogenesis. Therefore, the seeming implication of glucose metabolism in brain metastasis 
might not be as simple as Warburg-driven ATP generation. While glycolysis may immediately 
suggest ATP generation, it can actually serve as a substrate for biomass generation as well 
(227). As both increased glycolysis (191) and increased use of other metabolic substrates (192) 
have been reported in the context of brain metastasis, it will be important to identify whether 
the seemingly disparate functions of glycolysis and gluconeogenesis are time- or space-
dependent manifestations of metastatic response to nutrient limitations within the brain. Isotopic 
tracing experiments would allow the fate of these metabolic substrates to be revealed, thereby 
exposing which particular nutrients are limiting during the process of brain metastasis. 
Targeting of the salvage pathways by which brain metastases obtain limited nutrients may allow 
for creation of an evolutionary double bind scenario for metastasis targeting. 
In addition to glucose metabolism, at least two other networks revealed themselves in 
the screen. The first, calcium signaling, was indicated by the presence of CALM2, CALM3, and 
CAMK4. Calcium signaling is critical for brain function. It is involved in astrocyte-neuron 
communication (228), synaptic glutamate receptor activation leads to an influx of Ca2+ into 
neurons, which can trigger  transcriptional changes (229), and ionic calcium entry into neuronal 
mitochondria stimulates oxidative phosphorylation (230) and is coupled to synaptic vesicle 
release (231). In the context of cancer, calcium signaling has been shown to be activated in 
prostate cancer following stimulation with bone ECM (232); calcium may also stimulate cell 
migration (233). Interestingly, in the context of brain metastasis, transport of calcium from 
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cancer cells to astrocytes has been shown to be chemoprotective to cancer cells (234). Lastly, 
brain metastatic breast cancer cells have been shown to express GABAergic neuronal features 
(235). It is plausible that they could also express glutaminergic neuronal receptors, thus 
enabling enhanced calcium influx and calcium-mediated signaling. Though not yet validated, 
the fact that several calcium signaling proteins were enriched in brain metastasis in vivo 
suggests an important role for calcium signaling in brain metastasis. 
Another interesting pathway revealed by the screen is the CDK5/CDK5R1/PCTK1 axis. 
CDK5 and PCTK1 are both non-canonical CDKs, and CDK5R1 is a specific regulator of CDK5. 
The three proteins are expressed in the brain and have been shown to interact in vitro and in 
vivo (213); phosphorylation of PCTK1 by the CDK5/CDK5R1 complex at S95 enhances its 
activity. In a screen of over 350 kinases that yielded 31 hits, the odds of three members of the 
same complex being enriched accidentally are small. 
  However, in regards to which kinase ought to have been pursued further, the screen 
results alone were not sufficiently informative. For example, which putative hit would have been 
better to investigate, the one that is enriched 10-fold in two animals, or the one enriched 1.5-
fold in all mice of a group? While a larger sample size per group may have allowed for purely 
quantitative measurements, including differential weighting of positive and negative selection, 
this analysis was simple: if the average expression of a kinase in brain metastases of a group 
was greater than the input cells, and if at least two animals in the group had expression >1 
relative to input cells, the kinase was deemed a hit. Therefore, to further functionally rank the 
putative hits, a secondary screen was performed assaying single kinase-overexpressing MDA-
MB-231 cells for growth in hard agar (209). This assay simultaneously measures both the 
tumor-initiating capacity and invasive phenotype, both characteristics important for brain 
metastasis growth. Most kinases were able to enhance the hard agar colony formation relative 
to vector cells, some more than 100-fold, thus further prioritizing the hits.      
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In spite of the notable relationships existing within the putative hit kinases and their 
enhanced hard agar colony-forming ability, the kinome screen was built upon the principle of 
functional artificial heterogeneity: kinases were overexpressed in a cell line and queried for their 
potential to enhance brain metastasis growth without regard for whether or not they are actually 
expressed in brain metastasis. Therefore, prior to fully committing to a certain path, it was 
necessary to confirm that the putative hits were actually expressed in brain metastasis and not 
mere artifacts of this artificial heterogeneity approach. While NGS data on human brain 
metastasis is incredibly rare, an Australian group recently published NGS data on 36 human 
brain metastases, including 10 cases from breast cancer (205). Through a collaboration, the 
kinase hits identified in the screen were analyzed in their data. The results showed that all but 
2 of the kinome screen hits are expressed in human brain metastases, and are therefore not 
simply screen artifacts. Provocatively, the top 7 genes, whose expression exceeded the upper 
outlier threshold of [Q3+1.5 x IQR], included CALM2, CALM3, HK2, PFKL, and PCTK1. Based 
on the rank-sum score of the kinase hits in hard agar colony formation and human brain 
metastasis, PCTK1 was selected for validation. 
PCTK1 overexpression in the MDA-MB-231 cell line indeed enhanced brain metastasis 
growth and decreased mouse survival in the experimental brain metastasis setting. The 
resulting metastases included large lesions in the ventricles and leptomeninges of the mouse 
brain, with long invasive extensions into the brain parenchyma. The corresponding vector cells 
exclusively formed smaller ventricular and leptomeningeal metastases, with only sparse 
micrometastases observed in the parenchyma. Because these observations were made using 
the H&E stained brain sections harvested from mice that had become moribund, they represent 
different time points and are not directly comparable; a repeat of the experiment could be 
performed with all animals sacrificed at a set time point. Likewise, as this data represents overt 
brain metastases, a repeated experiment could include the sacrifice groups of mice at early 
times post-injection to investigate whether PCTK1 is more important for cancer cell survival at 
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the early stages of dissemination, extravasation, and colonization or only once the tumors are 
actively growing in the brain. 
Out of curiosity as to whether PCTK1’s effect on brain metastasis was brain-specific or 
common to all tumor growth in vivo, the relative abilities of 231.PCTK1 and 231.vector to form 
primary mammary tumors in nude mice was assayed. While the experiment is still ongoing, as 
of this writing there are no significant differences in primary tumor formation due to PCTK1 
overexpression, suggesting its pro-growth effect may be metastasis-specific. However, in order 
to test whether the phenotype is brain metastasis-specific, additional in vivo experimental 
metastasis assays would be required to test whether PCTK1 enhances lung, bone, or even liver 
metastasis in the MDA-MB-231 model. 
When PCTK1 failed to show growth advantages in vitro, it was unsurprising due to its 
status as a non-canonical CDK. However, it also failed to enhance migration, which is one of 
its commonly reported phenotypes in myoblasts and neurons (212, 236, 237). Interestingly, 
PCTK1 overexpression significantly reduced invasion of MDA-MB-231 cells through Matrigel, 
which is especially striking in light of its enhancement of invasion through hard agar. Matrigel, 
which is produced by a specialized line of mouse sarcoma cells, consists of a variety of 
basement membrane proteins including laminin and Type IV collagen (238). The fact that 
PCTK1 overexpression actually decreases invasion through Matrigel could simply be an in vitro 
artifact due to the specific composition of Matrigel; after all, the same cells actually have a 
growth advantage in the stiff matrix of hard agar and extend projections into the brain 
parenchyma from the meninges in vivo.  Alternatively, it may indicate antagonistic pleiotropy of 
PCTK1 expression: if expressed in the primary tumor, it may actually decrease invasion through 
the basement membrane and extravasation. This would be suggestive of the fact that PCTK1’s 
functional benefit to metastases is limited to growth and survival at the metastatic site. 
Experiments involving the modulation of PCTK1 in a spontaneous brain metastasis system 
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such as HIM (239) or BBM (235) could be helpful in identifying whether PCTK1 truly inhibits 
invasion and intravasation in vivo.  
Because of the brain’s abundant supply of glutamine relative to other amino acids (194) 
and the literature reports of brain metastatic tumor cells metabolizing glutamine to obtain ATP 
and biomass (200), TCGA data was examined for potential correlations of PCTK1 expression 
with glutamine metabolism. Since no large-scale datasets of brain metastasis are available, 
PCTK1 expressional correlations were examined in primary breast cancer as well as primary 
brain tumors, with the rationale that the brain environment represents a set of constraints, and 
all tumors, both primary and metastatic, are subject to these rules. While there were some 
correlations of PCTK1 with glutamine metabolism in all 3 subtypes of primary breast cancer 
(with ASNS) and in glioblastoma (with glucosamine-fructose-6-phosphate transaminase 1, 
GFPT1). The majority of the strong correlations observed were in low-grade glioma, where 
correlations existed between PCTK1, ASNS, GLS, and GLS2, as well and PCTK1, CDK5, and 
CDK5R1. It is established that the BBB is intact in LGG (240), while the vascular permeability 
of GBM renders the BBB functionally irrelevant (241). Therefore, the presence of these 
underlying relationships in LGG is highly suggestive of the fact that glutamine metabolism is 
important for cancer cell survival in the unique nutrient environment of the brain, but once the 
BBB functional barrier is lost, the nutrient restriction is lifted and PCTK1 may no longer provide 
a growth advantage.   
 The strength of the correlations between PCTK1 and the glutamine metabolism pathway 
were intriguing enough to demand functional examination. Using BME, low glucose, low amino 
acid-containing media, the PCTK1-overexpressing cells and their controls were compared for 
their relative growth ability. The answer was clear: with PCTK1 overexpression, cells can 
survive in glutamine-supplemented BME; without either glutamine presence of PCTK1 
expression, the cells died. Attempts to grow the cells in similar concentrations of glutamate 
instead of glutamine did not enable cell proliferation or survival, suggesting that if the cancer 
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cells in the brain are involved in a glutamate-glutamine cycle, it is unlikely to be autocrine in 
nature. Since one of the crucial functions of astrocytes in the brain is to scavenge glutamate 
from the synapse, process it into glutamine, and deliver glutamine to neurons (242), the 
potential exists that cancer cells, which are known to interact with astrocytes, use this same 
pathway to obtain glutamine. 
 While the proliferative advantage enjoyed by PCTK1-overexpressing cells cultured in 
glutamine pointed to the cells’ utilization of glutamine for energy or biomass generation, it could 
simply be donating its amino group for purine biosynthesis and leaving the cell as glutamate 
(243). Thus it was necessary to test whether there was a difference in glutamine and glutamate 
uptake and release from cell culture media by cancer cells. Indeed, MS analysis showed that 
although not statistically significant, glutamine uptake is slightly enhanced by PCTK1 
overexpression. At the same time, net glutamate release into the media is actually lower in 
PCTK1-overexpressing cells. The combined increase in glutamine uptake and decrease in net 
glutamate release implies that the glutamine is being used as a fuel or mass substrate, although 
further MS experiments tracing the fate of glutamine’s carbons and nitrogens are necessary 
are necessary to confirm whether they are being used for energy or building blocks.  
 In order to test whether there was a functional requirement for PCTK1 in brain 
metastasis, the HCC1954Br cell line was selected. A HER2-overexpressing line, 1954Br forms 
large parenchymal brain metastasis lesions in nude mice. Furthermore, of all of the in vivo 
brain-selected cell lines in the lab, it had the highest endogenous expression of PCTK1. 
Therefore, when knockdown of PCTK1 extended the median survival of 1954Br-bearing mice 
by nearly 60%, it was quite striking. The fact that the brain H&E sections of 1954Br controls 
and PCTK1-knockdown cells appeared to be morphologically very similar, in spite of their 
differences in survival time, could indicate two possibilities. Either the PCTK1 expression 
recovered in vivo, either through loss of the shRNA plasmid or selection for a clone that had 
inefficient knockdown, or PCTK1 provides a growth advantage at the early stage of brain 
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colonization but is dispensable later. While IHC analysis of the same slides for PCTK1 
expression did reveal that PCTK1 expression can recover in vivo in the shRNA knockdown 
group, the expression of PCTK1 in all samples was heterogeneous. Therefore, the possibility 
still remains that there is spatiotemporal variability in the requirement for PCTK1 during the 
process of brain metastasis. To resolve the absolute necessity of PCTK1 and whether it is 
important only at certain stages of the brain metastatic process, experiments utilizing CRISPR-
Cas9-based knockout of PCTK1 of inducible shRNA against PCTK1 can be performed in vivo. 
 
Conclusions and future directions 
 Brain metastasis is a common and deadly malignancy for which the biomedical research 
has little in the way of understanding and even less in terms of treatment options. This study, 
an in vivo functional genomics screen aimed at identification of novel kinases driving brain 
metastasis, sought to better elucidate the biology of brain metastasis. The screen was 
successful in identifying 31 potential drivers of brain metastasis, most of which are indeed 
expressed in human brain metastases. The screen identified several hits related to glucose 
utilization in the brain, a pathway already identified in brain metastasis that serves as a positive 
control that this study’s underlying methodology was sound. Other interconnected networks 
identified by the screen included calcium signaling, which is of great importance to neural 
function but whose function in brain metastasis remains unclear, and the non-canonical CDK 
axis of CDK5R1-CDK5-PCTK1. I validated the functional importance of PCTK1 in enhancing 
brain metastasis growth by overexpression in the MDA-MB-231 model, and went on to show 
that PCTK1’s brain metastasis growth enhancement does not extend to primary tumors in the 
same model. Additionally, while PCTK1 did not convey proliferative or survival advantages in 
vitro under normal culture conditions, it did dramatically enhance these phenotypes in a 
glutamine-dependent manner when grown in a glucose and amino acid-limited medium that 
was supplemented with glutamine to mimic the nutrient environment of the brain. Finally, I 
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showed that stable knockdown of PCTK1 in a different breast cancer cell line delayed the 
mortality due to brain metastasis by nearly 60%. 
Future directions of this study will aim at identification of the molecular mechanism by 
which PCTK1 enables the enhanced utilization of glutamine. By performing MS tracing analysis 
of metabolites generated from isotopically labeled glutamine, it will be possible to identify 
exactly how brain metastatic cells may be utilizing glutamine, whether it be for fuel or 
biomolecule generation. Identification of metabolites will guide the search for a direct 
phosphorylation target of PCTK1, and identification of that PCTK1 substrate and its 
phosphorylation site, followed by validation of the pathway’s activation in clinical brain 
metastasis, could allow for the development of PCTK1-targeted therapy. Further studies 
involving inducible knockdowns of PCTK1 can also be performed to investigate the timing of 
PCTK1’s growth advantage in brain metastasis, and whether it is limited to the early 
colonization steps or throughout brain metastatic growth. Additionally, CRISPR-based knockout 
of PCTK1 will allow observation of whether PCTK1 is necessary for brain metastasis growth, 
as it would remove the possibility of selection for metastatic clones with inefficient knockdown 
of PCTK1.  
Furthermore, there are 30 additional unvalidated targets that have been identified by 
this study. While PCTK1 demonstrated a dramatic pro-brain metastasis phenotype, there could 
be several other, potentially more important kinases and pathways to investigate in brain 
metastasis. By using functional genomics, it was possible to identify the key barriers that cancer 
cells have to overcome for growth in the brain. The potential exists that re-establishing these 
barriers and forcing brain metastases into an evolutionary double bind could result in 
therapeutic efficacy heretofore unseen in this disease setting.   
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